WO1999031086A1 - Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists - Google Patents

Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists Download PDF

Info

Publication number
WO1999031086A1
WO1999031086A1 PCT/EP1998/007804 EP9807804W WO9931086A1 WO 1999031086 A1 WO1999031086 A1 WO 1999031086A1 EP 9807804 W EP9807804 W EP 9807804W WO 9931086 A1 WO9931086 A1 WO 9931086A1
Authority
WO
WIPO (PCT)
Prior art keywords
quinolin
methylpiperazin
urea
formula
naphth
Prior art date
Application number
PCT/EP1998/007804
Other languages
French (fr)
Inventor
Laramie Mary Gaster
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9726364.4A external-priority patent/GB9726364D0/en
Priority claimed from GBGB9726905.4A external-priority patent/GB9726905D0/en
Priority claimed from GBGB9800317.1A external-priority patent/GB9800317D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to EP98965729A priority Critical patent/EP1047691A1/en
Priority to CA002313125A priority patent/CA2313125A1/en
Priority to JP2000539010A priority patent/JP2002508366A/en
Publication of WO1999031086A1 publication Critical patent/WO1999031086A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel piperazine derivatives, processes for their preparation, and pharmaceutical compositions containing them.
  • WO 95/06044 and WO 95/06637 all disclose a series of piperazine derivatives which are said to possess 5HTi > receptor antagonist activity. These compounds are alleged to be of use in the treatment of various CNS disorders such as depression.
  • EPA 0533266/7/8 disclose a series of benzanilide derivatives which are said to possess 5-HTi j ⁇ receptor antagonist activity.
  • the 5-HT ⁇ rj) receptor was subsequently found to consist of a pair of gene products originally designated 5-HTi ) ⁇ and 5-HTj ) ⁇ receptors which have more recently been reclassified as 5-HTj ) and 5-HTJB receptors respectively.
  • the present invention therefore provides a compound of formula (I) or a salt thereof:
  • R a is selected from a group of formula (i), (ii) or (iii); Group of formula (i)
  • P' is phenyl, bicyclic aryl, a 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;
  • R1 is hydrogen, halogen, C j .galkyi, C3_6cycloalkyl. C ⁇ galkoxy. hydroxy. hydroxyCi. galkyl, hydroxyC ⁇ . ⁇ alkoxy, Ci- ⁇ alkoxyCi- ⁇ alkoxy, C j _6alkanoyl, nitro, trifluoromethyl, cyano.
  • R 9 , R 10 and R* 1 are independently hydrogen or C ⁇ _6alkyl and c is 1 to 4; a is 0, 1 or 2; and
  • R- is halogen, C i.galkyl, C3_6cycloalkyl, C3_6cycloalkenyl, C ⁇ alkoxy, Cj.galkanoyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO R 10 , CONR ⁇ R 1 1 , NR 10 R! 1 where RlO and R ⁇ are as defined above;
  • P ⁇ and P ⁇ are independently phenyl, bicyclic aryl, a 5- to 7- membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;
  • A is a bond or oxygen, S(O) m where m is 0 to 2, carbonyl, CH? or NR ⁇ where R ⁇ is hydrogen or C i .galkyl;
  • R! is as defined above for formula (i) or is a 5 to 7-membered heterocyclic ring, containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur, optionally substituted by C ⁇ .
  • R- and R ⁇ are independently halogen, Ci .galkyl, C3_6cycloalkyl, C3_6cycloalkenyl, C ⁇ _ galkoxy, C ⁇ .galkanoyl, aryl. acyloxy, hydroxy, nitro, trifluoromethyl, cyano. CO 2 RlO,
  • the ring E is a 5, 6 or 7 -membered carbocyclic ring optionally substituted by one or more C j. ⁇ alkyl groups, fused at the 2.3- or 3.4-positions of the adjacent phenyl ring, the ring E being optionally fused to a further phenyl ring optionally substituted by one or more substituents independently selected from C ⁇ galkyl and halo; a is 0. 1 or 2; and
  • R- is halogen, C ⁇ .galkyl, C3_6cycloalkyl, C3_6cycloalkenyl, C ⁇ alkoxy, C ⁇ .galkanoyl, aryl, acyloxy, hydroxy, nitro. trifluoromethyl, cyano, CO 2 R 10 , CONR 10 Rl 1 , NR 10 R! 1 where RI O and R ⁇ are as defined above;
  • L is a group of formula
  • D is nitrogen, carbon or a CH group
  • G is hydrogen or C ⁇ -. ⁇ alkyl providing that D is nitrogen or a CH group
  • R°l forms a group W where W is (CR ⁇ R ⁇ ) t where t is
  • X is nitrogen or carbon
  • R°l, Rb2 and R° are independently hydrogen, halogen, hydroxy, Cj.galkyl,
  • R c is hydrogen or Chalk 1
  • • — is a single bond when X is nitrogen or a single or double bond when X is carbon.
  • Ci .galkyl groups whether alone or as part of another group may be straight chain or branched.
  • the term 'acyloxy' is used herein to describe a group -OC(O)C [.galkyl.
  • the term 'aryl' is used herein to describe, unless otherwise stated, a group such as phenyl or naphthyl.
  • 'halogen ' is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine.
  • the bicyclic aryl group represented by ? P- .and or PJ which may be partially saturated, is preferably naphthyl.
  • examples of bicyclic heterocyclic rings represented by P J ? ⁇ and/or P ⁇ include isoquinoline. indole. benzofuran, benzothiophene. and most preferably quinoline.
  • Examples of 5 to 7 membered heterocyclic rings represented by pi , ? ⁇ and/or p3, include thienyl, furyl, pyrrolyl, triazolyl. imidazolyl. oxazolyl, thiazolyl. oxadiazolyl, isothiazolyl, isoxazolyl. thiadiazolyl, pyrimidyl, pyrazinyl. and most preferably pyridyl.
  • the heterocyclic and bicyclic heterocyclic groups listed above can be linked to the remainder of the molecule via a carbon atom or, when present, a suitable nitrogen atom.
  • P 1 is preferably a phenyl, naphthyl or quinoline group.
  • P ⁇ is preferably phenyl or naphthyl.
  • R! is preferably a halogen atom most preferably, fluorine, chlorine or bromine, and R2 and/or R ⁇ are each preferably a halogen atom preferably, chlorine or bromine, or a C j . galkyl group for example a methyl group.
  • A is preferably a bond or oxygen.
  • the ring E in addition to the keto group and the portion fused to the phenyl ring, is preferably formed from a straight chain alkylene grouping containing 2, 3 or 4 carbon atoms.
  • the ring E is preferably a 5 or 6-membered ring in which the oxo group is advantageously attached to a carbon atom adjacent to the phenyl ring, the ring E being preferably attached to the 3,4-positions of the latter phenyl ring.
  • the group L is preferably a group of formula:-
  • D is preferably nitrogen and G is preferably a hydrogen atom or together with R D * forms a group W, preferably -(CH 2 ) - or -(CH )3-.
  • Rb*, R°2 and R°3 are preferably hydrogen or a halogen atom most preferably bromine or chlorine, or a C ⁇ .galkoxy group for example methoxy, or R D 1 together with G forms a group W referred to above.
  • X is preferably nitrogen.
  • R c is preferably a C j.galkyl group for example methyl.
  • Particularly preferred compounds according to the invention include:- N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
  • Preferred salts of the compounds of formula (I) are pharmaceutically acceptable salts. These include acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates. tartrates, citrates, oxalates, methanesulphonates and p- toluenesulphonates.
  • acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates. tartrates, citrates, oxalates, methanesulphonates and p- toluenesulphonates.
  • R a , Rbl . Rb2 ⁇ Rb3 ? R C ⁇ d x are .as defined in formula (I) and L 1 and L ⁇ contain the appropriate functional groups which are capable of reacting together to form the L moiety; or
  • R a -NC( O) (IV) in which R a is as defined in formula (I) or a protected derivative thereof, with a compound of formula (V):
  • L l is COL and L 2 is NH 2
  • L 1 is NH 2
  • L 2 is COL a in which L a is an appropriate leaving group.
  • one of L.1 and L- is an activated carboxylic acid derivative such as an acyl chloride or acid anhydride, and the other is an amine group.
  • Activated compounds of formulae (II) and (III) can also be prepared by reaction of the corresponding carboxylic acid with a coupling agent such as dicyclohexylcarbodiimide. carbonyldiimidazole or diphenylphosphorylazide.
  • a coupling agent such as dicyclohexylcarbodiimide. carbonyldiimidazole or diphenylphosphorylazide.
  • Li or L 2 is a group COL a where L a is halo particularly chloro.
  • reaction in process (b) is conveniently effected in an organic solvent such as dichloromethane.
  • the urea forming agent can be carbonyl diimidazole. triphosgene or phosgene, and carried out in an inert organic solvent such as dimethylformamide, tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
  • the leaving group IJ may be a halogen e.g. chloro group and the reaction may be carried out in an inert organic solvent such as tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
  • an inert organic solvent such as tetrahydrofuran or dichloromethane
  • a base such as triethylamine or pyridine.
  • the leaving group L 3 may be a halogen e.g. chloro group and the reaction may be carried out in an inert organic solvent such as tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
  • an inert organic solvent such as tetrahydrofuran or dichloromethane
  • a base such as triethylamine or pyridine.
  • Carboxylic acid groups can be protected as esters.
  • Aldehyde or ketone groups can be protected as acetals. ketals. thioacetals or thioketals. Deprotection is achieved using standard conditions.
  • Serotonin (5-hydroxytryptamine; 5HT) receptors have been implicated in a number of pharmacological effects including mood disorders including depression, seasonal affective disorder and dysthymia, anxiety disorders, including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders, including dementia, amnesic disorders and age-associated memory impairment; disorders of eating behaviours, including anorexia nervosa and bulimia nervosa, sleep disorders (including disturbances of Circadian rhythm), motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders.
  • mood disorders including depression, seasonal affective disorder and dysthymia
  • anxiety disorders including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder
  • memory disorders including dementia, amnesic disorders and
  • Serotonin receptor ligands have been shown to be of use in the treatment of emesis and nausea and may also be of use in endocrine disorders such as hyperlactinaemia, vasospasm (particularly in the cerebral vasculature), cerebellar ataxia and hypertension, as well as disorders ofthe gastrointestinal tract where changes in motility and secretion are involved. They may also be of use in the treatment of sexual dysfunction and hypothermia.
  • WO 95/31988 refers to the use of a 5-HTJ D receptor antagonist in conjunction with a 5-HTIA receptor .antagonist to treat CNS (central nervous system), endocrine and GI (gastrointestinal) disorders;
  • K. Rasmussen Annual Reports in Medicinal Chemistry, (1995) 30, 1) describes the utility of 5-HTj A receptor agonists and partial agonists in the treatment of various CNS disorders;
  • P. Trouillas Progress in Brain Research. C.I. de Zeeuw, P. Stara and J. Voogd, Eds. 1997, + . 589) and G. Maura (J.
  • the present invention also provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of the aforementioned disorders.
  • the invention provides a method of treating the aforementioned disorders which comprises administering an effective amount to a patient in need of such treatment of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • the invention provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment or prophylaxis of depression.
  • 5-HT ⁇ g and 5-HT I Q receptors can be determined by the following radioligand binding assay.
  • HEK 293 cells expressing 5-HTJA. receptors (4 x 10 ⁇ /ml) are homogenised in Tris buffer and stored in lml aliquots.
  • CHO cells expressing 5-HTjg receptors (4 x 10 ⁇ cells/ml) are homogenised in Tris buffer and stored in 1.5 ml aliquots.
  • CHO cells expressing 5-HTi ) receptors (0.563 x 10 ⁇ /ml) are homogenised in Tris buffer and stored in 1 ml aliquots.
  • the intrinsic activity of the compounds of this invention can be determined according to the following procedure.
  • HEK293 cell membranes stably expressing human 5-HT ⁇ ⁇ receptors and CHO cell membranes stably expressing human 5-HT ⁇ g receptors are homogenised in HEPES/EDTA buffer and stored in lml aliquots, and [ 3 ⁇ S]GTP ⁇ S binding studies are carried out essentially as described by Lazareno et al.. (Life Sci.. 1993, 52, 449) with some minor modifications.
  • Membranes from 10° " cells are pre-incubated at 30°C for 30 min in 20 mM HEPES buffer (pH 7.4) in the presence of MgCh (3 mM), NaCl (100 mM), GDP (10 ⁇ M) and ascorbate (0.2 mM), with or without compounds.
  • the reaction is started by the addition of 10 ⁇ l of [ 3 - S]GTP ⁇ S (100 pM, assay concentration) followed by a further 30 minutes incubation at 30°C.
  • Non-specific binding was determined using non- radiolabelled GTP ⁇ S (20 ⁇ M) added prior to the membranes.
  • the reaction is terminated by rapid filtration through Whatman GF/B grade filters followed by 5 x 1 ml washes with ice cold HEPES (20 mM) /MgCl 2 (3 mM) buffer. Radioactivity is measured using liquid scintillation spectrometry. This procedure is hereafter referred to as the [ ⁇ S]GTP ⁇ S functional assay.
  • the compounds of formula (I) show high affinity for the 5HT ⁇ A , 5-HTj ⁇ and 5-HT J E) receptors. It has been found, using the [-°S]GTP ⁇ S functional assay, that certain compounds of formula (I) show varying levels of intrinsic efficacy, which is defined by a scale ranging from 1.0 to 0 (1 defines the maximum response elicited by the agonist 5-HT, 0 defines antagonism).
  • the difficulties in describing intrinsic activity of drugs acting at G protein coupled receptors is recognised in the art (Hover and Boddeke, Trends in Pharmacological Sciences, July 1993, [Vol. 14], page 270-275).
  • the compounds of this invention will be useful antidepressants in vivo. It is believed that the preferred compounds of this invention will display 5HT I A, 5-HTj ⁇ and 5-HTJ Q antagonist activity in vivo and that such compounds will have a rapid onset of action.
  • a rapid onset of action is particularly advantageous for antidepressant compounds: by 'rapid onset of action' we mean that a therapeutic response is seen within 7 days from first administration of the compound, as opposed to a period of about 21 days or more which is typical of SSRI's, tricyclic antidepressants and buspirone.
  • the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, a selective serotonin reuptake inhibitor (SSRJ) antidepressant.
  • SSRJ selective serotonin reuptake inhibitor
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and. as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients. such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and. if desired, conventional flavourings or colorants.
  • fluid unit dosage forms are prepared utilising a compound ofthe invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.
  • the title compound was prepared from 4-chloro-3-cyanoaniline (D9) and pyridin-4-ylboronic acid using a similar procedure to Description 3.
  • the crude product was purified by chromatography on silica gel eluting with ethyl acetate to give needles from ether (8%), mp
  • the mixture was stirred well at 0-5°C for 1 hour, then diluted with water (20ml) and extracted with dichloromethane. The extract was dried (Na 2 SO4) and cautiously concentrated under vacuum at room temperature to approx. 10ml volume. This solution was then treated with toluene (30ml) and gently heated under argon to reflux temperature and maintained for 0.5 hours. The reaction mixture was allowed to cool and the isocyanate solution used directly in the next step.
  • the title compound was prepared from 5-(2-methylpyridin-5-yl)-l-naphthoic acid (D29) using a similar procedure to Description 28.
  • the isocyanate was not isolated, but used in the next step as its toluene solution.
  • the title compound was prepared from 5-(2-methylpyridin-3-yl)-l-naphthoic acid (D31) using a similar procedure to Description 28.
  • the isocyanate was not isolated, but used in the next step as its toluene solution.
  • the title compound was prepared from 2-bromopyrimidine and 5-carboxynaphth-l-ylboronic acid (D26) using a similar procedure to Description 3 to afford the product as an off-white solid.
  • the title compound was prepared from 5-(pyrimidin-2-yl)-l-naphthoic acid (D33) using a similar procedure to Description 28.
  • the isocyanate was not isolated, but used in the next step as its toluene solution.
  • the title compound was prepared from diethyl 1 -benzyl- 1,2.3, 4-tetrahydroquinolin-6- ylaminojmethylenemalonate (D47, 9Jg, 223mmol) following a similar procedure to Description 38 (3J 8g. 37%).
  • the title compound was prepared from l-benzyl-9-(4-methylpiperazin-l-yl)- 1,2,3,4- tetrahydropyrido[2,3-g]quinolin-8-ylcarboxylic acid (D50, 2.5g, ⁇ .Ommol) following a similar procedure to Description 41 (lJg, 76%).
  • Finely ground N-[2-bromophenyl]glyoxamide oxime (D53, 292g, 0J2mol) was added portionwise to well stirred cone. H 2 SO4 (64ml) at 50°C maintaining an internal temperature of 50-70°C during the addition. The mixture was then heated to 80-85°C for 10 minutes, cooled to room temperature and poured onto crushed ice (600g) with stirring. A red/brown precipitate ofthe title compound formed. This was filtered off, washed with water and dried in a vacuum oven (14.8g, 55%).
  • the title compound was prepared from 8-bromoquinolin-4-ylcarboxylic acid (D56) using a similar procedure to Description 28.
  • the isocyanate was not isolated, but used in the next step as its toluene solution.
  • the title compound was prepared from 8-(2-fluorophenyl)quinolin-4-ylcarboxylic acid (D58) using a similar procedure to Description 28.
  • the isocyanate was not isolated, but used in the next step as its toluene solution.
  • the title compound was prepared from 8-(2-methoxyphenyl)quinolin-4-ylcarboxylic acid (D60) using a similar procedure to Description 28.
  • the isocyanate was not isolated, but used in the next step as its toluene solution.
  • CDCI3 ⁇ (ppm): 9.1 (s, IH), 8.95 (s, IH), 8.65 (d, 2H), 8.55 (d, IH), 8.5 (s, IH), 7.8 (d, IH), 7.6 (s, IH), 7.45 (d, IH), 7.3 (d, 2H), 7.2 (d, 2H), 6.8 (d, IH), 3.25 (br s, 4H), 2.65 (br s, 4H), 2.35 (s, 3H).
  • the title compound was prepared from 6-aminoquinoline and 6-amino-4-(4-methypiperazin- l-yl)quinoline (D2) following a similar procedure to Example 1 as a yellow powder from ether (1 1%), m.p. 240 - 250°C (dec).
  • the title compound was prepared from 4-(pyridin-4-yl)-3-trifluoromethylaniline (D8) and 6- amino-4-(4-methylpiperazin- 1 -yl)quinoline (D2) following a similar procedure to Example 1 as a yellow powder (47%).
  • the title compound was prepared from 5-cyano-l-naphthylamine (EP 456090) and 6-amino- 4-(4-methylpiperazin-l-yl)quinoline (D2) using a similar procedure to Example 1 as a pale buff solid (50%).
  • Example 1 The hydrochloride salt was isolated as a green powder (34%). ⁇ NMR (HCl salt) (250MHz. d 6 DMSO) ⁇ (ppm): 11.36 (s, IH), 1 1.05 (s. I H). 9.80 (s, IH), 8.76 (d. IH), 8.68 (d, IH), 8.59 (s, IH). 8.18 (q, 3H), 7.96 (d, IH), 7.76-7.64 (m. 2H), 7.33 (d. I H). 4.22 (br s. 2H), 3.62 (br s. 4H). 2.90 (s. 3H), 2.75 (s, 3H). 2H obscurred by H O signal.
  • the title compound was prepared from 5-(pyrimidin-2-yloxy)-l-naphthylamine (D23) and 6- amino-4-(4-methylpiperazin-l -yl)quinoline (D2) using a similar procedure to Example 1 as a pale yellow solid (10%).
  • Example 27 The free base was converted to monohydrochloride salt as a yellow solid from acetone.
  • the title compound was prepared from 5-(pyrimidin-2-yl)naphth-l-yl isocyanate (D34) and 6-amino-4-(4-methylpiperazin-l -yl)quinoline (D2) using a similar procedure to that described for Example 27.
  • the free base was converted to monohydrochloride salt, as a yellow solid.
  • the title compound was prepared from 4-(pyridin-4-yl)-l-naphthylamine (D5) and 2,3- dihydro-8-(4-methylpiperazin-l-yl)pyrrolo[2,3-g]quinoline (D42) using a similar procedure to Example 1 as the hydrochloride salt, a yellow solid (67%).
  • the title compound was prepared from 5-(pyrimidin-2-yloxy)-l-naphthylamine (D23) and 23-dihydro-8-(4-methylpiperazin-l-yl)pyrrolo[2,3-g]quinoline (D42) using a similar procedure to Example 1 as the hydrochloride salt, a yellow solid (47%).
  • the title compound was prepared from 6-amino-3,4-dihydro-l(2H)-naphthalenone and 6- amino-4-(4-methylpiperazin-l-yl)quinoline (D2) using a similar procedure to Example 1 as a yellow foam (47%).
  • the title compound was prepared from 5-amino-l-indanone and 6-amino-4-(4- methylpiperazin-l-yl)quinoline (D2) using a similar procedure to Example 1 as a yellow foam (20%).
  • affinities of the compounds of this invention were determined by methods described above.
  • 5-HTJ A > 5-HTJ B and 5-HTJ D Receptor Binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to compounds of formula (I) or a salt thereof in which Ra is selected from a group of formula (i), (ii) or (iii); L is a group of formula -Y-C(=O)-DG- or -C(=O)-DG- or -DG-C(=O)- in which Y is -NH-, NR5 where R5 is C¿1-6?alkyl, or Y is -CH2- or -O-; D is nitrogen, carbon or a CH group, or G is hydrogen or C1-6alkyl providing that D is nitrogen or a CH group, or G together with R?b1¿ forms a group W where W is (CR16R17)t where t is 2, 3 or 4 and R?16 and R17¿ are independently hydrogen or C¿1-6?alkyl or W is (CR?16R17)¿u-J where u is 0, 1, 2 or 3 and J is oxygen, sulphur, CR?16=CR17, CR16=N, =CR16O, =CR16¿S or =CR16-NR17 provided that u is not 0 when J is oxygen or sulphur; X is nitrogen or carbon; R?b1, Rb2 and Rb3¿ are independently hydrogen, halogen, hydroxy, C¿1-6?alkyl, C2-6alkenyl, C3-6cycloalkyl, trifluoromethyl, C1-6alkoxy or aryl, or R?b1¿ together with G forms a group W as defined above; Rc is hydrogen or C¿1-6?alkyl; and ------- is a single bond when X is nitrogen or a single or double bond when X is carbon; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.

Description

QUINOLINEPIPERAZINE AND QUINOLINEPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS COMBINED 5-HT1A, 5-HT1B AND 5-TH1D RECEPTOR ANTAGONISTS
The present invention relates to novel piperazine derivatives, processes for their preparation, and pharmaceutical compositions containing them.
WO 95/04729. WO 95/06044 and WO 95/06637 all disclose a series of piperazine derivatives which are said to possess 5HTi > receptor antagonist activity. These compounds are alleged to be of use in the treatment of various CNS disorders such as depression. EPA 0533266/7/8 disclose a series of benzanilide derivatives which are said to possess 5-HTij} receptor antagonist activity. The 5-HTιrj) receptor was subsequently found to consist of a pair of gene products originally designated 5-HTi )α and 5-HTj )β receptors which have more recently been reclassified as 5-HTj ) and 5-HTJB receptors respectively. (Hartig, P.R. et al., Trends in Pharmacological Sciences 1992, Vol. 13, page 152. Hartig, P.R. et al., Trends in Pharmacological Sciences. 1996, Vol. 17, page 103).
A structurally distinct class of compounds have now been found that exhibit combined 5HTι^, 5HTJB and 5HTID receptor affinity. It is expected that such compounds will be useful for the treatment and prophylaxis of various disorders. In a first aspect, the present invention therefore provides a compound of formula (I) or a salt thereof:
Figure imgf000003_0001
in which Ra is selected from a group of formula (i), (ii) or (iii); Group of formula (i)
Figure imgf000003_0002
in which P' is phenyl, bicyclic aryl, a 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur; R1 is hydrogen, halogen, C j .galkyi, C3_6cycloalkyl. C^galkoxy. hydroxy. hydroxyCi. galkyl, hydroxyC \ .^alkoxy, Ci-^alkoxyCi-^alkoxy, C j _6alkanoyl, nitro, trifluoromethyl, cyano. SR9, SOR9, SO2R9, SO2NR10R1 1, CO2 10, CONR^R1 1, CONRlO(CH2)cCO2R1 1. (CH2)CNR10R11, (CH2)CCONR10R1 1, (CH2)cNR10CORl 1 , (CH2)cCO2C!.6alkyl. CO2(CH2)cOR10, NR10R! 1 , NR^CO^R1 1, NRI OCONRI ORI 1 , CR10=NOR1 1 , CNR^NOR1 where R9, R10 and R* 1 are independently hydrogen or Cι_6alkyl and c is 1 to 4; a is 0, 1 or 2; and
R- is halogen, C i.galkyl, C3_6cycloalkyl, C3_6cycloalkenyl, C ^alkoxy, Cj.galkanoyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO R10, CONR^R1 1, NR10R! 1 where RlO and R^ are as defined above;
Group of formula (ii)
Figure imgf000004_0001
wherein P^ and P^ are independently phenyl, bicyclic aryl, a 5- to 7- membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;
A is a bond or oxygen, S(O)m where m is 0 to 2, carbonyl, CH? or NR^ where R^ is hydrogen or C i .galkyl;
R! is as defined above for formula (i) or is a 5 to 7-membered heterocyclic ring, containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur, optionally substituted by C \ .
6alkyl, halogen or C^galkanoyl; a and b are independently 0, 1 or 2; and
R- and R^ are independently halogen, Ci .galkyl, C3_6cycloalkyl, C3_6cycloalkenyl, C \_ galkoxy, C \ .galkanoyl, aryl. acyloxy, hydroxy, nitro, trifluoromethyl, cyano. CO2RlO,
CONR^R1 1, NR^R1 1 where R10 and R1 ] are as defined above;
Group of formula (iii) (R2)a
0 = C E _
(iϋ) in which the ring E is a 5, 6 or 7 -membered carbocyclic ring optionally substituted by one or more C j.^alkyl groups, fused at the 2.3- or 3.4-positions of the adjacent phenyl ring, the ring E being optionally fused to a further phenyl ring optionally substituted by one or more substituents independently selected from C^galkyl and halo; a is 0. 1 or 2; and
R- is halogen, C ^.galkyl, C3_6cycloalkyl, C3_6cycloalkenyl, C^alkoxy, C \ .galkanoyl, aryl, acyloxy, hydroxy, nitro. trifluoromethyl, cyano, CO2R10, CONR10Rl 1 , NR10R! 1 where RI O and R^ are as defined above;
L is a group of formula
- Y-C(=O)-DG - or -C(=O)-DG- or -DG-C(=O)- in which Y is - NH -, NR5 where R5 is C^aUcyl, or Y is - CH - or - O -;
D is nitrogen, carbon or a CH group, G is hydrogen or C \ -.βalkyl providing that D is nitrogen or a CH group, or G together with R°l forms a group W where W is (CR^R^)t where t is
2, 3 or 4 and R^ and R^ are independently hydrogen or Cj.galkyl or W is (CR^ 1 )U_J where u is 0, 1 , 2 or 3 and J is oxygen, sulphur, CR16=CR1 7, CR16=N, =CR16O, =CR 6s or =CR16_NR17 provided that u is not 0 when J is oxygen or sulphur;
X is nitrogen or carbon;
R°l, Rb2 and R° are independently hydrogen, halogen, hydroxy, Cj.galkyl,
C2_6alkenyl, C3_6cycloalkyl, trifluoromethyl, C ^^alkoxy or aryl, or R"l together with G forms a group W as defined above;
Rc is hydrogen or Chalk 1; and
•— is a single bond when X is nitrogen or a single or double bond when X is carbon.
Ci .galkyl groups whether alone or as part of another group may be straight chain or branched. The term 'acyloxy' is used herein to describe a group -OC(O)C [.galkyl. The term 'aryl' is used herein to describe, unless otherwise stated, a group such as phenyl or naphthyl.
- j - The term 'halogen' is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine.
The bicyclic aryl group represented by ? P- .and or PJ which may be partially saturated, is preferably naphthyl.
Within the definition of Ra formula (i) and (ii). examples of bicyclic heterocyclic rings represented by P J ?~ and/or P^ include isoquinoline. indole. benzofuran, benzothiophene. and most preferably quinoline. Examples of 5 to 7 membered heterocyclic rings represented by pi , ?~ and/or p3, include thienyl, furyl, pyrrolyl, triazolyl. imidazolyl. oxazolyl, thiazolyl. oxadiazolyl, isothiazolyl, isoxazolyl. thiadiazolyl, pyrimidyl, pyrazinyl. and most preferably pyridyl. The heterocyclic and bicyclic heterocyclic groups listed above can be linked to the remainder of the molecule via a carbon atom or, when present, a suitable nitrogen atom.
P 1 is preferably a phenyl, naphthyl or quinoline group. P^ is preferably phenyl or naphthyl.
R! is preferably a halogen atom most preferably, fluorine, chlorine or bromine, and R2 and/or R^ are each preferably a halogen atom preferably, chlorine or bromine, or a C j . galkyl group for example a methyl group.
Within the definition of Ra formula (ii), A is preferably a bond or oxygen.
Within the definition of Ra formula (iii) the ring E, in addition to the keto group and the portion fused to the phenyl ring, is preferably formed from a straight chain alkylene grouping containing 2, 3 or 4 carbon atoms. The ring E is preferably a 5 or 6-membered ring in which the oxo group is advantageously attached to a carbon atom adjacent to the phenyl ring, the ring E being preferably attached to the 3,4-positions of the latter phenyl ring.
The group L is preferably a group of formula:-
-NH-C(=O)-(DG)- or -CH2-C(=O)-(DG)- in which D is preferably nitrogen and G is preferably a hydrogen atom or together with RD* forms a group W, preferably -(CH2) - or -(CH )3-.
Rb*, R°2 and R°3 are preferably hydrogen or a halogen atom most preferably bromine or chlorine, or a C \ .galkoxy group for example methoxy, or RD 1 together with G forms a group W referred to above.
X is preferably nitrogen.
Rc is preferably a C j.galkyl group for example methyl.
Particularly preferred compounds according to the invention include:- N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[4-(pyridin-4-yl)naphth-l -yl]-urea,
N-[4-(4-Methylpiperazin- 1 -y l)quinoiin-6-y l]-N'-[5-(pyridin-4-yl)naphth- 1 -y l]-urea
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[quinolin-6-yl]-urea.
4-Bromo-N-[4-(4-methylpiperazin- 1 -y l)quinolin-6-yl]naphth- 1 -ylacetamide.
5-Bromo-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]naphth-l-ylacetamιde.
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-4-(pyridin-4-yl)naphth-l -ylacetamide,
N-[4-(4-Methylpiper∑ιzin-l-yl)quinolin-6-yl]-5-(pyridin-4-yl)naphth-l -ylacetamide,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[4-(pyridin-4-yl)-3-trifluoromethylphenyl]- urea,
N-[3-Cyano-4-(pyridin-4-yl)phenyl]-N'-[4-(4-methylpiper^in-l-yl)quinolin-6-yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[quinolin-5-yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[quinolin-8-yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[quinolin-3-yl]-urea,
2J-Dichloro-N-[4-(4-methylpiper^in-l-yl)quinolin-6-yl]phenylacetamide,
5-(4-Acetylphenyl)-N-[4-(4-methylpiper.azin- 1 -yl)quinolin-6-yl]naphth- 1 -ylacetamide,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[quinolin-4-yl]-urea,
N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[4-(l-methylpiperidin-4-yl)quinolin-6-yl]-urea,
N-[3-Methyl-4-(6-methylpyridin-2-yl)phenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]- urea,
N-[4-(2,6-Dimethylpyridin-4-yl)-3-methylphenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6- yl]-urea,
N-[5-Cyanonaphth-l-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[5-(5-Methyl- 1 J,4-oxadiazol-3-y l)naphth- 1 -yl]-N'-[4-(4-methylpiperazin- 1 -y l)quinolin-6- yl]-urea,
N-[4-(4-MethyIpiperazin- 1 -y l)quinolin-6-yl]-N'-[5-(pyrimidin-2-yloxy)naphth- 1 -yl]-urea,
N-[5-Acetylnaphth-l-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[5-Bromonaphth-l-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea.
N-[5-(6-Methylpyridin-2-yl)naphth- 1 -yl]-N'-[4-(4-methylpiperazin- 1 -yl)quinolin-6-yl]-urea,
N-[5-(2-Methylpyridin-5-yl)naphth- 1 -yl]-N'-[4-(4-methylpiperazin- 1 -y l)quinolin-6-yl]-urea,
N-[5-(2-Methylpyridin-3-yl)naphth- 1 -yl]-N'-[4-(4-methylpiperazin- 1 -y l)quinolin-6-yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[5-(pyrimidin-2-yl)naphth-l-yl]-urea,
N-[5-Bromonaphth-l-yl]-N'-[4-(piperazιn-l-yl)quinolin-6-yl]-urea,
2,3-Dihydro-8-(4-methylpiperazin- 1 -yl)- 1 -[4-(pyridin-4-yl)naphth- 1 - ylaminocarbonyl]pyrrolo[2J-g]quinoline, 2J-Dihydro-8-(4-methylpiperazin- 1 -yl)- 1 -[5-(5-methyl- 1 J.4-oxadiazol-3-yl)naphth- 1 - ylaminocarbonyl]pyrrolo[2J-g]quinoline,
2J-Dihydro-8-(4-methylpiperazin- 1 -yl)- 1 -[5-(pyrimidin-2-y loxy)naphth- 1 - ylaminocarbonyl]pyrrolo[2J-g]quinoline,
9-(4-Methylpiperazin- 1 -yl)- 1 -[4-(pyridin-4-yl)naphth- 1 -ylaminocarbonyl]- 1 ,2,3,4- tetrahydropyrido[2,3-g]quinoline,
9-(4-Methylpiperazin- 1 -yl)- 1 -[5-(pyrimidin-2-yloxy)naphth- 1 -ylaminocarbonyl]- 1 ,2,3,4- tetrahydropyrido[2.3-g]quinoline,
N-[8-Bromoquinolin-4-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[8-(2-Fluorophenyl)quinolin-4-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea.
N-[8-(2-Methoxyphenyl)quinolin-4-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[2-Biphenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[2J-Dichlorophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N'-[4-Biphenyl]-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[3,4-Dichlorophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[4-Chlorophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[3-Cyanophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[4-phenoxyphenyl]-urea,
N-[4-Bromophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-ιιrea,
N-[4-Acetylphenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-ιιrea,
N-[2-Bromophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[3,5-Bis(trifluoromethyl)phenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[3-AcetyIphenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[2,6-DifluorophenyI]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[3-Bromophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yI]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[naphth-l-yl]-urea,
N-[2,6-Dichlorophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[4-Chloro-2-methylphenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[4-Bromo-3-methylphenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-2-nitrophenylacetamide,
4-Bromo-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]phenylacetamide,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-4-biphenylacetamide,
3,4-Dichloro-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]benzamide,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]naphth-2-ylacetamide,
4-Dimethylamino-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]phenylacetamide, 3,4-Difluoro-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]phenylacetamide,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-3-phenoxyphenylacetamide.
N-[4-(4-Methylpiperazin- 1 -y l)quinolin-6-yl]naphth- 1 -ylcarboxamide.
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-4-phenoxybenzamide.
N-[4-(4-Methylpiper^in-l-yl)quinolin-6-yl]-N'-[5,6,7,8-tetrώydro-5-oxo-2-naphthalenyl]- urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[5-oxoindan-2-yl]-urea,
2,3-Dihydro-8-(4-methylpiperazin-l-yl)-l -[(5,6,7, 8-tetrahydro-5-oxo-2- naphthalenyl)aminocarbonyl]pyrrolo[2J-g]quinoline,
9-(4-Methylpiperazin- 1 -yl)- 1 -[(5-oxo-5,6,7,8-tetrahydronaphth-6-yl)aminocarbonyl]- 1 ,2,3,4- tetrahydropyrido[2,3-g]quinoline or pharmaceutically acceptable salts thereof.
Preferred salts of the compounds of formula (I) are pharmaceutically acceptable salts. These include acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates. tartrates, citrates, oxalates, methanesulphonates and p- toluenesulphonates.
Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and the mixtures thereof including racemates.
Compounds ofthe invention can be prepared using procedures known in the art. In a further aspect the present invention provides a process for the preparation of a compound of formula (I) which comprises
(a) where L is -C(=O)-DG - or -DG-(C=O)-, coupling a compound of formula (II):
Ra -L* (II) with a compound of formula (III):
Figure imgf000010_0001
in which Ra, Rbl . Rb2} Rb3? RC ^d x are .as defined in formula (I) and L 1 and L^ contain the appropriate functional groups which are capable of reacting together to form the L moiety; or
(b) where L is - Y -C(=O)-DG in which D is nitrogen and Y is NH, coupling a compound of formula (IV):
Ra -NC(=O) (IV) in which Ra is as defined in formula (I) or a protected derivative thereof, with a compound of formula (V):
N
GNH
,b3
R b1 t>2
R'
(V) in which Rbl, Rb2^ Rb3; RC G and X are as defined in formula (I), or a protected derivative thereof: or
(c) where L is - Y -C(=O)-DG - in which D is nitrogen and Y is NH or NR3, reacting a compound of formula (VI) Ra -NH2 or Ra -NR5H (VI) in which Ra and R3 are as defined in formula (I) with a compound of formula (V) together with an appropriate urea forming agent; or
(d) where L is - Y -C(=O)-DG - in which D is nitrogen and Y is CH2 or O, reacting a compound of formula (VII): a _γ_ (c=0) - L3 (VII) in which Ra is as defined in formula (I), and L3 is an appropriate leaving group, with a compound of formula (V); or
(e) where L is - Y -C(=O)-DG - in which D is CH and Y is NH, reacting a compound of formula (VI):
Ra -NH2 (VI) in which Ra is as defined in formula (I) with a compound of formula (VIII):
Rc
N
X
L3 DG- j — Rb3 pbi N
R Rb2
(VIII) in which D, G. X, Rbl, Rb2, Rb3 and RC r^e as defined in formula (I) and L3 is an appropriate leaving atom; and optionally thereafter:
• removing any protecting groups,
• converting a compound of formula (I) into another compound of formula (I),
• forming a pharmaceutically acceptable salt.
In the reaction of the compounds of foimulae (II) and (III), suitable examples of groups Li and L2 include:-
Ll is COL and L2 is NH2 L1 is NH2 and L2 is COLa in which La is an appropriate leaving group.
Suitably one of L.1 and L- is an activated carboxylic acid derivative such as an acyl chloride or acid anhydride, and the other is an amine group. Activated compounds of formulae (II) and (III) can also be prepared by reaction of the corresponding carboxylic acid with a coupling agent such as dicyclohexylcarbodiimide. carbonyldiimidazole or diphenylphosphorylazide. Preferably Li or L2 is a group COLa where La is halo particularly chloro.
Compounds of formulae (II) and (III) are typically reacted together in an inert solvent such as dimethylformamide, tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as an alkali metal hydroxide, triethylamine or pyridine.
The reaction in process (b) is conveniently effected in an organic solvent such as dichloromethane.
In process (c) the urea forming agent can be carbonyl diimidazole. triphosgene or phosgene, and carried out in an inert organic solvent such as dimethylformamide, tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
In process (d) the leaving group IJ may be a halogen e.g. chloro group and the reaction may be carried out in an inert organic solvent such as tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
In process (e) the leaving group L3 may be a halogen e.g. chloro group and the reaction may be carried out in an inert organic solvent such as tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
Compounds of formula (I) can be converted into further compounds of formula (I) using standard techniques. For example, in the case wherein Rc is hydrogen, it is possible to introduce a C^galkyl group by conventional alkylation using 1 molar equivalent of a Cj.galkyl halide and 1 molar equivalent of a suitable base in an inert solvent.
Intermediate compounds of formula (II) to (VIII) can be prepared using standard procedures known in the art.
It will be appreciated to those skilled in the art that it may be necessary to protect certain reactive substituents during some of the above procedures. Standard protection and deprotection techniques can be used. For example, primary amines can be protected as phthalimide, benzyl, benzyloxycarbonyl or trityl derivatives. These groups can be removed by conventional procedures well known in the art.
Carboxylic acid groups can be protected as esters. Aldehyde or ketone groups can be protected as acetals. ketals. thioacetals or thioketals. Deprotection is achieved using standard conditions.
The involvement of serotonin receptors in a number of pharmacological effects has been reviewed by R. A. Glennon in "Serotonin Receptors: Clinical Implications", Neuroscience and Behavioural Reviews, 1990, j_4, 35 and by L.O. Wilkinson and C.T. Dourish in "Serotonin Receptor Subtypes : Basic and Clinical Aspects" S. Peroutka Ed., John Wiley and Sons. New York, 1991 p.147.
Serotonin (5-hydroxytryptamine; 5HT) receptors have been implicated in a number of pharmacological effects including mood disorders including depression, seasonal affective disorder and dysthymia, anxiety disorders, including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders, including dementia, amnesic disorders and age-associated memory impairment; disorders of eating behaviours, including anorexia nervosa and bulimia nervosa, sleep disorders (including disturbances of Circadian rhythm), motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders. Serotonin receptor ligands have been shown to be of use in the treatment of emesis and nausea and may also be of use in endocrine disorders such as hyperlactinaemia, vasospasm (particularly in the cerebral vasculature), cerebellar ataxia and hypertension, as well as disorders ofthe gastrointestinal tract where changes in motility and secretion are involved. They may also be of use in the treatment of sexual dysfunction and hypothermia.
Ligands with high affinity for the 5HTj receptors .are well recognised as having therapeutic utility for the treatment of the above conditions. For example: WO 95/31988 refers to the use of a 5-HTJ D receptor antagonist in conjunction with a 5-HTIA receptor .antagonist to treat CNS (central nervous system), endocrine and GI (gastrointestinal) disorders; K. Rasmussen (Annual Reports in Medicinal Chemistry, (1995) 30, 1) describes the utility of 5-HTj A receptor agonists and partial agonists in the treatment of various CNS disorders; P. Trouillas (Progress in Brain Research. C.I. de Zeeuw, P. Stara and J. Voogd, Eds. 1997, + . 589) and G. Maura (J. Neurochemistry, 1996. 66. 202) propose that administration of agonist ligands selective for the 5-HTj^ receptor or for both 5-HTj^ and 5-HTi ) receptors should provide effective treatment for human cerebellar ataxias. The present invention also provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of the aforementioned disorders.
In a further aspect the invention provides a method of treating the aforementioned disorders which comprises administering an effective amount to a patient in need of such treatment of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof.
In particular the invention provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment or prophylaxis of depression.
The affinities ofthe compounds of this invention for the 5HTι A. 5-HTιg and 5-HT I Q receptors can be determined by the following radioligand binding assay. HEK 293 cells expressing 5-HTJA. receptors (4 x 10^/ml) are homogenised in Tris buffer and stored in lml aliquots. CHO cells expressing 5-HTjg receptors (4 x 10^ cells/ml) are homogenised in Tris buffer and stored in 1.5 ml aliquots. CHO cells expressing 5-HTi ) receptors (0.563 x 10^/ml) are homogenised in Tris buffer and stored in 1 ml aliquots.
0.4 ml of a cell suspension is incubated with [3H]-5-HT (4nM) for 5-HT J B/I Q receptors and [3H]-8-OH DPAT (InM) for 5-HT1 A receptors in Tris Mg HCl buffer (pH 7.7) and test drug, at 37°C for 45 minutes. Each test drug is tested at 10 concentrations (0.01 mM to 0.3 nM final concentration), with non-specific binding defined using 0.01 mM 5-HT. The total assay volume is 0.5 ml. Incubation is stopped by rapid filtration using a Packard Filtermate (filters pre-soaked in 0.3% polyethylenimine) and radioactivity measured by Topcount scintillation counting. pKi values are calculated from the IC50 generated by an iterative least squares curve fitting programme.
The intrinsic activity of the compounds of this invention can be determined according to the following procedure. HEK293 cell membranes stably expressing human 5-HTι ^ receptors and CHO cell membranes stably expressing human 5-HTιg receptors are homogenised in HEPES/EDTA buffer and stored in lml aliquots, and [3^S]GTPγS binding studies are carried out essentially as described by Lazareno et al.. (Life Sci.. 1993, 52, 449) with some minor modifications. Membranes from 10°" cells are pre-incubated at 30°C for 30 min in 20 mM HEPES buffer (pH 7.4) in the presence of MgCh (3 mM), NaCl (100 mM), GDP (10 μM) and ascorbate (0.2 mM), with or without compounds. The reaction is started by the addition of 10 μl of [3- S]GTPγS (100 pM, assay concentration) followed by a further 30 minutes incubation at 30°C. Non-specific binding was determined using non- radiolabelled GTPγS (20 μM) added prior to the membranes. The reaction is terminated by rapid filtration through Whatman GF/B grade filters followed by 5 x 1 ml washes with ice cold HEPES (20 mM) /MgCl2 (3 mM) buffer. Radioactivity is measured using liquid scintillation spectrometry. This procedure is hereafter referred to as the [ ^S]GTPγS functional assay.
The compounds of formula (I) show high affinity for the 5HTιA, 5-HTjβ and 5-HT J E) receptors. It has been found, using the [-°S]GTPγS functional assay, that certain compounds of formula (I) show varying levels of intrinsic efficacy, which is defined by a scale ranging from 1.0 to 0 (1 defines the maximum response elicited by the agonist 5-HT, 0 defines antagonism). The difficulties in describing intrinsic activity of drugs acting at G protein coupled receptors is recognised in the art (Hover and Boddeke, Trends in Pharmacological Sciences, July 1993, [Vol. 14], page 270-275). We believe that however these ligands are classified according to this functional assay, the compounds of this invention will be useful antidepressants in vivo. It is believed that the preferred compounds of this invention will display 5HT I A, 5-HTjβ and 5-HTJ Q antagonist activity in vivo and that such compounds will have a rapid onset of action. A rapid onset of action is particularly advantageous for antidepressant compounds: by 'rapid onset of action' we mean that a therapeutic response is seen within 7 days from first administration of the compound, as opposed to a period of about 21 days or more which is typical of SSRI's, tricyclic antidepressants and buspirone.
Compounds of formula (I) which have an intrinsic activity of 0.5 or less in the [j:5S]GTPγS functional assay are particularly preferred, as these compounds are more likely to be full antagonists in vivo. As disclosed in WO 95/31988, the simultaneous antagonism of pre-synaptic HT I A/I B/1 D receptors will result in increased release of 5HT in vivo and this will improve 5HT neurotransmission.
It will be appreciated by those skilled in the art that the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, a selective serotonin reuptake inhibitor (SSRJ) antidepressant.
The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and. as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients. such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and. if desired, conventional flavourings or colorants.
For parenteral administration, fluid unit dosage forms are prepared utilising a compound ofthe invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.
The following Examples illustrate the preparation of compounds of the invention. Description 1 4-(4- ethyIpiperazin-l-yI)-6-nitroquinoline (DI)
4-Chloro-6-nitroquinoline (J. Org. Chem. 1944, 9, 302) (2.08g, O.OlmoI) and 4- methylpiperazine (l .OOg, O.Ol moI) were stirred together in DMF (20ml). Triethylamine (2ml) was added and the mixture was stirred at 50°C under argon for lόhours. The solvent was evaporated in vacua and the residue partitioned between 20% aqueous K2CO3 and dichloromethane. The organic phase was washed with water, dried (Na2SO4) and evaporated to give an oil, which was purified by chromatography on silica using methanol/dichloromethane to give the title compound (2.03g, 75%). lH NMR (250MHz, CDC13) δ (ppm): 9.0 (d 1H), 8.82 (d, 1H), 8.40 (dd. 1H), 8.24 (d, 1H), 6.95 (d, 1H), 3.35 (m, 4H), 2.75 (m, 4H), 2.46 (s, 3H). MS: m/z = 273 (MH+).
Description 2 6-Amino-4-(4-methylpiperazin-l-yl)quinoIine (D2)
4-(4-Methylpiperazin-l-yl)-6-nitroquinoline (DI, 1.92g, 7.05mmol) was dissolved in ethanol
(70ml), Raney nickel (0.1 g) was added and the mixture hydrogenated at room temperature and atmospheric pressure until the uptake of hydrogen had ceased. The catalyst was removed by filtration and the filtrate evaporated in vacuo to yield the title compound as an oil (1.59g,
93%). iH NMR (250MHz, CDCI3) δ (ppm): 8.45 (d, 1H), 7.85 (dd, 1H), 7.18 (m. 2H), 6.79 (d,
1H), 3.98 (s, 2H), 3.19 (m, 4H), 2.66 (m, 4H), 2.41 (s, 3H). MS: m/z = 243 (MH+).
Description 3 3-Chloro-4-(pyridin-4-yl)acetanilide (D3)
4-Bromo-3-chloroacetanilide (8.0g, 32.2mmol) in dimethoxyethane (300ml) and water (200ml) was treated with pyridin-4-ylboronic acid (4g, 32mmol) and Na CO3 (10.24g, 97mmol) and the reaction degassed by bubbling argon through the mixture for 30 minutes. The reaction was then treated with tetrakis(triphenylphosphine)palladium (0) and refluxed under argon for 24 hours. The reaction was concentrated in vacuo to low volume and the residue partitioned between 5M HC1 and dichloromethane. The aqueous layer was separated and carefully neutralised with 2M NaOH and the resulting solid collected by filtration to give the title compound (5.0g, 63%). i H NMR (250MHz. d6DMSO) δ (ppm): 10.45 (s, IH), 8.7 (d, 2H), 8.05 (s, IH), 7.65 (d, IH). 7.55 (d, 2H), 7.5 (d, IH), 2.2 (s. 3H). Description 4 3-ChIoro-4-(pyridin-4-yl)aniline (D4)
3-Chloro-4-(pyridin-4-yl)acetanilide (D3, 5g, 20.3mmol) in 2M NaOH (100ml) and ethanol
(100ml) was heated at reflux under argon for 36 hours. The reaction was then concentrated in vacuo to remove the ethanol and the product recovered by extraction into CH C1 . The organic extract was dried (Na SO4) and evaporated in vacua to afford the title compound
(3.5g, 84%). iH NMR (250MHz. CDC13) δ (ppm): 8.65 (d, 2H). 7.35 (d. 2H), 7.15 (d. IH). 6.8 (s. IH),
6.65 (s, IH), 3.95 (br s, 2H).
Description 5 4-(Pyridin-4-yl)-l-naphthylamine (D5)
The title compound was prepared from 4-bromo-l-naphthylamine and pyridin-4-ylboronic acid using a similar procedure to Description 3 as a yellow crystalline solid (78%). iH NMR (250 MHz. CDCI3) δ (ppm): 8.68 (d, 2H), 7.90 (d, 2H), 7.30 (m, 5H), 6.84 (d, lH), 4.32 (s, 2H)
Description 6 5-(Pyridin-4-yl)-l-naphthylamine (D6)
The title compound was prepared from 5-bromo-l-naphthylamine (JP 08151353A2) and pyridin-4-ylboronic acid using a similar procedure to Description 3 as a yellow solid (61%). 'H NMR (250 MHz. CDC13) δ (ppm): 8.75 - 8.67 (m, 2H), 7.93 (d, IH), 7.70 - 7.35 (m, 4H), 7.28 - 7.20 (m, 2H). 6.85 - 6.80 (m. IH), 4.25 (s, 2H).
Description 7 4-(Pyridin-4-yl)-3-trifluoromethylacetanilide (D7)
The title compound was prepared from 4-bromo-3-trifluoromethylacetanilide and pyridin-4- ylboronic acid using a similar procedure to Description 3 (59%). ! H NMR (250MHz CDCI3) δ (ppm): 8.65(d, 2H), 8.4 (s, IH), 7.9(m, 2H), 7.3(m, 3H), 2.25(s, 3H).
Description 8 4-(Pyridin-4-yl)-3-trifluoromethyIaniline (D8)
The title compound was prepared from 4-(pyridin-4-yl)-3-trifluoromethylacetanilide (D7) using a similar procedure to Description 4 (95%). l H NMR (250MHz CDCI3) δ (ppm):8.6(m. 2H), 7.25(m, 2H) 7.05 (m. 2H), 6.85 (m, IH), 4.0 (s. 2H).
Description 9 4-Chloro-3-cyanoaniline (D9)
2-Chloro-5-nitrobenzonitrile ( 18.2g, 100 mmol) in ethanol (500ml) at reflux under an atmosphere of argon was treated over 30 minutes with tin (II) chloride (75.6g, 400 mmol). The exothermic reaction required little additional heating. After cooling, the reaction mixture was concentrated in vacuo to a gum, which was partitioned between NaOH solution and CH2C12. The organic phase was separated, dried (Na2SO4) and concentrated in vacuo to a gum, which was chromatographed on silica gel eluting with 3-10% MeOH CH2Cl to give the title compound as needles (6.5g, 43%), mp 124-126°C. Η NMR (250MHZ, CDCI3) δ (ppm): 7.25 (d, IH), 6.95 (s, IH), 6.8 (d. IH). 4.0 (br s, 2H).
Description 10 3-Cyano-4-(pyridin-4-yl)aniline (D10)
The title compound was prepared from 4-chloro-3-cyanoaniline (D9) and pyridin-4-ylboronic acid using a similar procedure to Description 3. The crude product was purified by chromatography on silica gel eluting with ethyl acetate to give needles from ether (8%), mp
131-133°C.
Η NMR (250 MHz, CDC13) δ (ppm): 8.7 (d, 2H), 7.45 (d, 2H), 7.35 (d, IH), 7.05 (s, IH),
6.95 (d, 1H), 4J (br s, 2H).
Description 11 2,3-Dichlorophenylacetonitriie (DI 1)
A stirred suspension of 2,3-dichlorobenzyl chloride (20g, OJO mol) in ethanol (140ml) and water (10ml) was treated with sodium cyanide (6g, 0J2 mol) in water (25ml), heated under reflux for 8 hours and then left to stand overnight. The reaction mixture was concentrated in vacuo and partitioned between dichloromethane and aqueous K9CO3 solution. The organic layer was dried 4(Na SO4), concentrated in vacuo, washed with petroleum ether and dried in vacuo to afford the title compound (14.59g, 77%). ! H NMR (250 MHz CDCI3) δ(ppm) : 7.56-7.39 (m, 2H), 7.32-7.15 (m, I H). 3.91 (s, 2H).
Description 12
Ethyl 2,3-dichlorophenyiacetate (D12) A stirred suspension of 2J-dichlorophenylacetonitrile (DI 1. 14g, 75 mmol) in ethanol (200ml) was treated with concentrated sulphuric acid (20ml) and heated under reflux for 3 days. The reaction mixture was then concentrated in vacuo and partitioned between dichloromethane and water. The organic layer was separated, dried (Na2SO4) and concentrated in vacuo to afford the title compound (16.45g, 94%). iH NMR (250 MHz. CDC13) δ(ppm) : 7.4-7.3 (m, IH), 7.2-7.15 (m, 2H), 4.20-4.18 (q, 2H). 3.75 (s, 2H), 1.27-1.15 (t, 3H)
Description 13 2 -Dichlorophenylacetic acid (D13)
A stirred suspension of ethyl 2.3-dichlorophenylacetate (D12, 4.4g, 19 mmol) in 5M HC1 acid (300 ml) was heated under reflux overnight. The reaction mixture was concentrated in vacuo to afford the title compound (2.5g, 65%). iH NMR (250 MHz, CDCI3) δ(ppm) 7.45-7.36 (m, IH), 7.23-7.12 (m, 2H),3.85 (s, 2H).
Description 14 6-Nitro-4-(pyridin-4-yl)quinoline (D14)
The title compound was prepared from 4-chloro-6-nitroquinoline (J. Org. Chem. 1944, 9, 302) and pyridin-4-ylboronic acid using a similar procedure to Description 3 (63%). 'H NMR (250MHZ, CDC13) δ (ppm): 9.2 (d, IH), 8.9 (d, 2H), 8.8 (s, IH). 8.55 (dd, IH), 8.35 (d, IH), 7.5 (d, lH), 7.45 (d, 2H).
Description 15 l-Methyl-4-(6-nitroquinolin-4-yI)pyridinium iodide (D15)
6-Nitro-4-(pyridin-4-yl)quinoline (D14, 500mg, 2 mmol) in acetone (100ml) was treated with iodomethane (2.8g, 20mmol) and the reaction heated under reflux for 2 hours, then cooled to room temperature. The title compound which precipitated was collected by filtration (6 lOmg, 80%).
'H NMR (250 MHz, d6DMSO) δ (ppm): 9.35 (d, IH), 9.25 (d, 2H), 8.65 (s, IH), 8.6 (d, IH), 8.5 (d, 2H), 8.45 (d, IH), 7.9 (d, IH), 4.5 (s, 3H).
Description 16
6-Amino-4-(l-methylpiperidin-4-yl)quinoIine hydroiodide (D16) l-Methyl-4-(6-nitroquinolin-4-yl)pyridinium iodide (D15, 300mg. 0.78 mmol) in methanol (25ml) was treated with platinium dioxide (150ml) and the suspension stirred under an atmosphere of hydrogen for 4 hours. The reaction was then filtered through Kieselghur and concentrated in vacuo to give a green oil (300mg).
Η NMR (250MHZ. CD3OD) δ (ppm): 8.3 (d. IH), 7.65 (d, IH). 7.25 (s, IH), 7.15 (d, IH),
7.1 (d, IH), 3.5-3.2 (3H, m). 3.05-2.9 (m, 2H). 2.65(s, 3H), 2.1-1.75 (m, 4H). NH2 not observed.
Description 17 4-Amino-2-methylphenylboronic acid (D17)
A stirred solution of 4-bromo-3-methylaniline (20g, 0J07 mol) and triethylamine (33ml, 0.237 mol) in dichloromethane (250ml) at 0°C under argon was treated dropwise over 15 minutes with a solution of bis(chlorodimethylsilyl)ethane (25 Jg, 0J2 mol) in dichloromethane (100ml). The mixture was warmed to room temperature and stirred for 20 hours, then filtered and concentrated in vacuo. The residue was extracted with 60-80 petrol (400ml) and the filtrate concentrated in vacuo to leave the stabase as an orange oil (35g, 100%)). This was dissolved in dry THF (400ml), coled to -65°C under argon and treated dropwise over 15 min with 2.5M n-butyllithium in hexane (52ml, 0J3mol). The mixture was stirred at -65°C for 1 hour, then treated dropwise over 10 min with triisopropylborate (30ml, 0J3 mol), stirred at -65°C for a further 1.5 hours, then treated with saturated aqueous NH4C1 solution (100ml) and allowed to warm to room temperature. The mixture was diluted with water (200ml), acidified with cone. HC1 acid (50ml), stirred for 20 min, then concentrated under vacuum to approx. 400ml volume. The aqueous residue was washed with ethyl acetate and then basified by addition of solid K2CO3. The basic mixture was extracted with ethyl acetate and the extract dried (Na,SO4) and concentrated in vacuo to approx. 150ml volume, when a solid began to precipitate out. The mixture was cooled to 8°C and the solid filtered off and dried to afford the title compound as a white solid (9Jg, 51%)). Η NMR (250MHz, d6DMSO) δ (ppm): 7.69 (d, IH), 6.40-6.32 (m, 2H), 5.34 (br s, 2H), 2.52 (s, 3H). Acid protons not observed.
Description 18 3-MethyI-4-(6-methylpyridin-2-yl)aniline (D18)
The title compound was prepared from 2-bromo-6-methylpyridine and 4-amino-2- methylphenylboronic acid (D17) using a similar procedure to Description 3 as beige solid
(100%).
Η NMR (250MHz, CDC1,) δ (ppm): 7.62-7.55 (m. IH), 7.22 (d. IH), 7.15 (d. IH), 7.05 (d,
IH), 6.62-6.55 (m, 2H), 3.68 (br s, 2H), 2.59 (s, 3H), 2.31 (s, 3H). Description 19 4-(2,6-Dimethylpyridin-4-yl)-3-methyianiline (D19)
The title compound was prepared from 4-chloro-2.6-dimethylpyridine (Chem. Abs. 1952, 46, 4541 ) and 4-amino-2-methylphenylboronic acid (D17) using a similar procedure to Description 3 as beige solid (4%).
Η NMR (250MHZ. CDC13) δ (ppm): 7.01 (d, IH), 6.90 (s, 2H). 6.62-6.54 (m. 2H), 3.70 (br s. 2H), 2.55 (s, 6H), 2.22 (s, 3H).
Description 20 5-Nitronaphth-l-yIamidoxime (D20)
A stirred solution of sodium hydroxide (0,44g, 1 1 mmol) in methanol (100ml) was treated with hydroxylamine hydrochloride (0J6g, 1 1 mmol). The mixture was gently warmed and then 5-nitronaphth-l-ylcarbonitrile (EP 456090) was added and the resultant mixture heated at relux for 36 hours. The cooled mixture was concentrated in vacuo to 10ml. water (50ml) was added and the precipitate collected by filtration, washed with water and dried in vacuo to afford the title compound as a pale yellow powder (lJ2g, 88%).
Η NMR (250MHz. d6DMSO) δ (ppm): 9.74 (s, IH), 8.67 (d, IH), 8.33 (m. 2H), 7.76-7.70 (m, 3H), 6.15 (s. 2H).
Description 21 5-Methyl-3-(5-nitronaphth-l-yl)-l,2,4-oxadiazole (D21)
A stirred solution of 5-nitronaphth-l-ylamidoxime (D20, 1.28g, 5.5mmol) in pyridine (10ml) was treated with acetyl chloride (0.78ml, 1 lmmol). The mixture was stirred at room temperature for 0.5 hours, then heated at reflux for 24 hours. The cooled mixture was poured into water (100ml) and extracted with ethyl acetate (3 x 25ml). The combined extract was washed with dilute HC1 acid and water, dried (Na2SO4) and concentrated to dryness in vacuo. The residue was purified by flash chromatography on silica gel eluting with CH2C12. The title compound was isolated as a pale yellow solid (0.86g, 61%). Η NMR (250MHZ. CDC13) δ (ppm): 927 (d, IH), 8.67 (d, IH), 8.34 (d, IH), 8.20 (d, IH), 7.81 (dd, IH), 7.68 (dd, IH), 2.75 (s, 3H).
Description 22 5-(5-Methyl-l,2,4-oxadiazol-3-y-)-l-naphthylamine (D22) A stirred suspension of 5-methyl-3-(5-nitronaphth-l-yl)-lJ.4-oxadiazole (D21 , lOOmg, 0.4mmol) in ethanol (8ml) and water (4ml) was treated with iron powder ( 1 lOmg, 1.96mmol) and ammonium chloride ( 1 lmg, OJlmmol) and the mixture heated to reflux for 1 hour. The mixture was cooled, filtered through celite and the filtrate concentrated to dryness. The residue was dissolved in ethyl acetate (25ml), washed with water, dried (Na2SO4) and concentrated to dryness. The title compound was isolated as its hydrochloride salt as a yellow/green solid (1 lOmg, 85%).
Η NMR (HCl salt) (250MHz, d"DMSO) δ (ppm): 8.73 (t, IH). 8.10 (d, IH), 7.94 (d. 1H0, 7.60 (t, IH), 7.41 (d. 2H), 2.47 (s, 3H). Amine signal obscured by water peak.
Description 23 5-(Pyrimidin-2-yloxy)-l-naphthylamine (D23)
A stirred mixture of 5-hydroxy-l-naphthylamine (0.5 lg, 3 mmol), 2-bromopyrimidine (0.48g, 3mmol) and anhydrous potassium carbonate (0.4 lg, 3mmol) in dry DMF (5ml) was heated to 1 10°C under argon for 4 hours. The mixture was concentrated to dryness in vacuo and the residue treated with water (30ml) and extracted with ethyl acetate (3 x 30ml). The combined extract was dried (Na SO4) and concentrated to dryness in vacuo. The residue was triturated with ether to afford the title compound as a pale buff solid (0.4 lg, 58%). Η NMR (250MHz, d6DMSO) δ (ppm): 8.55 (d, 2H), 7.75 (d, IH), 7.48 (t, IH), 7.39-7.18 (m, 3H), 7.02 (t, IH), 6.78 (d, IH), 4.13 (s, 2H).
Description 24 5-Acetyl-l-naphthylamine (D24)
A stirred solution of 5-nitro-l -acetonaphthone (Aust. J. Chem., 1995, 48. 1969) (0.75g, 3.5mmol) and 10% Pd-C (OJOg) in cyclohexene (10ml) and methanol (75ml) was heated at reflux for 6h. The cooled mixture was filtered, concentrated to dryness in vacuo and the residue dissolved in CH2C12 (50ml), washed with water (20ml), dried (Na2SO4) and concentrated to dryness. The residue was triturated in diethyl ether/Tiexane to afford the title compound as yellow/brown solid (0.52g, 80%).
Η NMR (250MHz, CDC13) δ (ppm): 8.03 (t, 2H), 7.83 (dd. 1 H0, 7.49-7.36 (m. 2H), 6.82 (d. IH), 4.17 (s, 2H), 2.73 (s, 3H).
Description 25
5-Bromonaphth-l-yl isocyanate (D25) The title compound was prepared from 5-bromo-l-naphthoic acid (Bull. Soc. Chim. Fr., 1968. 7. 2957) using a similar procedure to Description 28. The isocyanate was not isolated, but used in the next step as its toluene solution.
Description 26 5-Carboxynaphth-l-ylboronic acid (D26)
A stirred solution of 5-bromo- l-naphthoic acid (Bull. Soc. Chim. Fr.. 1968, 7. 2957) (22.3g, 0.089 mol) in dry THF (1000ml) at -60CC under argon was treated dropwise over 15 minutes with 1.6M n-butyllithium in hexane ( 125ml, 0.20 mol). The initial brown solution gave a beige precipitate as the first equivalent was added, which redissolved on addition ofthe second equivalent. The resulting solution was stirred at -60°C for 40 minutes, then triisopropylborate (51ml, 0.22 mol) was added, and the mixture stirred at -60°C for a further lh. before warming gradually to -10°C. Saturated aqueous NH4C1 solution (300ml) was added, followed by water (400ml) and then 5M HCl acid (200ml). The resulting mixture was concentrated in vacuo to approx. 1000ml volume, then basified by addition of 40% NaOH solution and washed with ethyl acetate. The aqueous was added to excess 5M HCl acid and the solid which precipitated out was filtered off, washed with water and dried to afford a white solid (9.67g), which contained approx. 50% of the title compound together with 1- naphthoic acid.
Description 27
5-(6-Methylpyridin-2-yl)-l-naphthoic acid (D27)
The title compound was prepared from 2-bromo-6-methylpyridine and 5-carboxynaphth-l- ylboronic acid (D26) using a similar procedure to Description 3 as beige solid (46%).
Η NMR (250MHz, d6DMSO) δ (ppm): 8.90 (d, IH), 8.13 (d, IH), 8.06 (dd, IH), 7.84 (t,
I H). 7.67 (t, IH), 7.62-7.46 (m, 2H), 7.41 (d, IH), 7.32 (d, IH), 2.55 (s. 3H). Acid proton not observed.
Description 28
5-(6-Methylpyridin-2-yl)naphth-l-yi isocyanate (D28)
A suspension of 5-(6-methylpyridin-2-yl)-l-naphthoic acid (D27. 400mg, 1.5 mmol) in dichloromethane (25ml) was treated with oxalyl chloride (0.26ml. 3.0 mmol) and stirred at room temperature for 20 hours, then concentrated in vacuo. The residue was suspended in dichloromethane (30ml) and shaken quickly with ice-cold NaHCO3 solution (20ml). The organic solution was immediately separated and added to a stirred solution of sodium azide (195mg, 3.0 mmol) and tetrabutylammonium iodide (35mg) in water (15ml) at 5°C. The mixture was stirred well at 0-5°C for 1 hour, then diluted with water (20ml) and extracted with dichloromethane. The extract was dried (Na2SO4) and cautiously concentrated under vacuum at room temperature to approx. 10ml volume. This solution was then treated with toluene (30ml) and gently heated under argon to reflux temperature and maintained for 0.5 hours. The reaction mixture was allowed to cool and the isocyanate solution used directly in the next step.
Description 29 5-(2-MethyIpyridin-5-yl)-l-naphthoic acid (D29)
The title compound was prepared from 5-bromo-2-methylpyridine and 5-carboxynaphth-l- ylboronic acid (D26) using a similar procedure to Description 3 as beige solid (64%). Η NMR (250MHz, d6DMSO) δ (ppm): 13.3 (br s, IH), 8.90 (d. I H), 8.53 (s, IH), 8.15 (d, IH), 7.93 (d, IH), 7.83-7.67 (m, 2H), 7.62-7.47 (m, 2H), 7.43 (d, IH), 2.57 (s, 3H).
Description 30
5-(2-Methylpyridin-5-yl)naphth-l-yl isocyanate (D30)
The title compound was prepared from 5-(2-methylpyridin-5-yl)-l-naphthoic acid (D29) using a similar procedure to Description 28. The isocyanate was not isolated, but used in the next step as its toluene solution.
Description 31 5-(2-Methylpyridin-3-yI)-l-naphthoic acid (D31)
The title compound was prepared from 2-methyl-3-iodopyridine and 5-carboxynaphth-l- ylboronic acid (D26) using a similar procedure to Description 3 as beige solid (61%). Η NMR (250MHz, d6DMSO) δ (ppm): 133 (br s, IH), 8.91 (d, IH), 8.59 (dd, IH), 8.15 (dd, IH), 7.78-7.69 (m, IH), 7.64 (dd, IH), 7.60-7.45 (m, 3H), 7.43-7.35 (m, IH), 2.13 (s. 3H).
Description 32
5-(2-Methylpyridin-3-yl)naphth-l-yl isocyanate (D32)
The title compound was prepared from 5-(2-methylpyridin-3-yl)-l-naphthoic acid (D31) using a similar procedure to Description 28. The isocyanate was not isolated, but used in the next step as its toluene solution.
Description 33 5-(Pyrimidin-2-yl)-l-naphthoic acid (D33)
The title compound was prepared from 2-bromopyrimidine and 5-carboxynaphth-l-ylboronic acid (D26) using a similar procedure to Description 3 to afford the product as an off-white solid.
Η NMR (250 MHz, d6DMSO) δ (ppm): 13.15 (br, IH). 9.05 (d, IH), 8.98 (dJH), 8.88 (d,
IH), 8J0 (d, IH), 8J 5 (mJH), 8.04 (mJH), 7.75 (t, IH), 7.60 (m. 2H).
Description 34
5-(Pyrimidin-2-yl)naphth-l-yI isocyanate (D34)
The title compound was prepared from 5-(pyrimidin-2-yl)-l-naphthoic acid (D33) using a similar procedure to Description 28. The isocyanate was not isolated, but used in the next step as its toluene solution.
Description 35 l-Benzyl-5-nitroindoline (D35)
To a stirred solution of 5 -nitro indo line (50g, OJOmol) in acetone (500ml) was added anhydrous potassium carbonate (55Jg, 0.40mol) followed by dropwise addition of benzyl bromide (42ml, 0J5mol) over 45 minutes. The mixture was stirred at room temp for 24 hours. Further benzyl bromide (10.0ml, 0.08mol) and potassium carbonate (12.0g, 0.09mol) were added and the mixture heated at reflux for 3 days. On cooling, the mixture was filtered and the filtrate evaporated in vacuo to a dark red oil. Trituration with hexane afforded the title compound as an orange crystalline solid (79. Og, 100%).
!H NMR (250MHZ, CDCI3) δ(ppm): 8.05 (d, IH), 7.91 (s. IH), 7.25-7.40 (m. 5H), 6.35 (d, IH), 4.35 (s, 2H), 3.63 (t, 2H). 3.09 (t, 2H). MS: m z = 255 (MH+)
Description 36 5-Amino-l-benzylindoline (D36)
A mixture of l-benzyl-5-nitroindoline (D35, 20.0g, 0.08mol), tin(II)chloride (60.0g, 0J2mol) and cone. HCl (40ml) in methanol (400ml) was heated at reflux for 16h. On cooling, the mixture was evaporated in vacuo to a red oil, which was partitioned between CH C12 and water, basified with 40% NaOH solution and the insoluble tin residues removed by filtration. The filtrate was extracted with CH C12 (2x), dried (Na2SO4) and evaporated in vacuo to afford the title compound as a dark green oil (lOJg. 60%). iH NMR (250MHz,CDCl3) δ(ppm): 7.23-7.41(m, 5H), 6.58 (s, IH). 6.45 (dd, IH), 6.37 (d, IH), 4.13 (s, 2H), 3.31 (br s, 2H), 3.18 (t. 2H), 2.87 (t, 2H). MS: m z = 225 (MH+) Description 37
Diethyl (l-benzyiindolin-5-ylamino)methylenemalonate (D37)
Diethyl ethoxymethylenemalonate (9.45ml, 0.05 mol) was added to a solution of 5-amino-l- benzylindoline (D36, 10.5g, 0.05mol) in toluene (500ml) and the mixture heated at reflux under argon for 1.5 hours. On cooling, the solvent was removed in vacuo to give a brown oil
(19.6g). Purification by flash chromatography eluting with hexane:EtOAc (70:30) afforded the title compound as a yellow crystalline solid (14Jg, 77%).
J H NMR (250MHz.CDCl3) δ(ppm): 8.42 (d, IH), 7.28-7.38 (m. 5H), 6.93 (s, IH), 6.83 (dd,
IH), 6.44 (d, 2H), 4.17-4.33 (m, 6H), 3.36 (t. 2H), 2.99 (t, 2H), 125-1.40 (m, 6H). MS: m/z
= 395 (MH+)
Description 38
Ethyl l-benzyl-8-chloro-2,3-dihydropyrrolo[2,3-g]quinolin-7-ylcarboxyiate (D38)
Diethyl (l-benzylindolin-5-ylamino)methylenemalonate (D37, 10. Og, 25Jmmol) in phosphorus oxychloride (40ml) was heated at reflux under argon for 2.5 hours. The mixture was concentrated in vacuo and the residual oil treated with 10% Na CO3 solution until basic. Extraction with CH C1 afforded a red gum which was purified using column chromatography eluting with hexane:EtOAc (70:30) to afford the title compound as a yellow crystalline solid (6.3g, 68%). iH NMR (250MHz, CDC13) δ(ppm): 8.81 (s, IH), 7.69 (s, IH), 727-7.40 (m, 5H), 7.02 (s, IH), 4.51 (s, 2H), 4.46 (q, 2H), 3.59 (t, 2H), 3.24 (t, 2H), 1.44 (t, 3H). MS: m z = 367 (MH+)
Description 39
Ethyl l-benzyl-2,3-dihydro-8-(4-methylpiperazin-l-yl)pyrrolo[2,3-g]quinolin-7- ylcarboxylate (D39)
To a mixture of ethyl l-benzyl-8-chloro-2J-dihydropyrrolo[2J-g]quinolin-7-ylcarboxylate (D38, 5.5g, 15.0mmol) and N-methylpiperazine (5.0ml. 45.0mmol) in DMF (50ml) was added triethylamine (6.3ml, 45.0mmol) and the mixture heated at 90°C under argon for 16 hours. The DMF was removed in vacuo and the residue partitioned between CH2C1 and water. The organics were separated and the aqueous further extracted with CH2C12 (lx). The combined organics were dried (Na2SO4) and evaporated in vacuo to an orange oil. which was triturated with ethyl acetate (x2) to give the title compound as a yellow solid (4.83g. 75%). ! H NMR (250MHz. CDCI3) δ(ppm): 8.54 (s, IH), 7.67 (s, IH), 729-7.41 (m, 5H). 6.76 (s. IH), 4.45 (s, 2H). 4.41 (q, 2H). 3.60 (t, 2H), 3.17-3.25 (m. 6H). 2.40 (br s, 4H), 2.30 (s, 3H), 1.40 (t, 3H). MS: m z = 431 (MH+)
Description 40 l-BenzyI-2,3-dihydro-8-(4-methylpiperazin-l-yl)pyrrolo[2,3-g]quinolin-7-ylcarboxylic acid (D40)
Ethyl l-benzyl-2J-dihydro-8-(4-methyl-l-piperazinyl)pyrrolo[2J-g]quinolin-7- ylcarboxylate (D39, 4.8g, 1 l Jmmol) in ethanol (100ml) was treated with a solution of sodium hydroxide (0.89g, 222mmol) in water (20ml) and the mixture heated at reflux under argon for 16 hours. The ethanol was removed in vacuo, the residue diluted with water and treated with 1M HCl solution to pH7. The yellow precipitate was filtered off and dried in a vacuum oven to afford the title compound (4.5g, 100%). iH NMR (250MHz. d6DMSO) δ(ppm): 8.35 (s, IH), 7.56 (s, IH), 7.39-7.55 (m, 5H), 6.73 (s. IH), 4.50 (s, 2H), 3.56 (t, 2H), 3.34 (br s, 4H), 3.16 (t, 2H), 2.87 (br s, 4H), 2.61 (s, 3H). Acid proton not observed. MS: m/z = 403 (MH+)
Description 41 l-Benzyl-2 -dihydro-8-(4-methylpiperazin-l-yl)pyrrolo[2,3-g]quinoline (D41) l-Benzyl-2J-dihydro-8-(4-methylpiperazin-l-yl)pyrrolo[2J-g]quinolin-7-ylcarboxylic acid (D40, 4.46g, 1 1 Jmmol) was added in small portions with care down an air condenser to diphenyl ether ( 100ml) at 250°C over 15 minutes. The mixture was heated at 250-270°C for a further 10 minutes and allowed to cool to 35°C. The solution was then poured into hexane (200ml) and extracted into 2M HCl solution. The acidic extracts were washed with hexane (4x) to remove the diphenyl ether and basified with 10% Na2CO3 solution. Extraction with ethyl acetate (3x) gave the title compound as a yellow crystalline solid (4.0g, 100%). iH NMR (250MHz, CDCI3) δ(ppm): 8.42 (d, IH), 7.68 (s. IH), 728-7.42 (m, 5H), 6.73 (d, IH), 6.61 (s, IH), 4.42 (s, 2H). 3.57 (t, 2H), 3.20 (t, 2H), 3.08 (br s, 4H), 2.42 (br s, 4H), 2.36 (s, 3H). MS: m/z = 359 (MH+)
Description 42 2,3-Dihydro-8-(4-methylpiperazin-l-yl)pyrrolo[2,3-g]quinoline (D42)
I -Benzyl-2.3-dihydro-8-(4-methylpiperazin- 1 -yl)pyrrolo[2.3-g]quinoline (D41. 3.98g,
I I Jmmol) and cone. HCl (4.0ml) in ethanol (50ml) was hydrogenated over 10% palladium on charcoal at 50psi (J44.8KPa) and room temperature for 30 hours. The mixture was filtered through Celite (Diatomaceous Earth) and basified with solid K Cθ3. Evaporation gave an off white solid which was dissolved in CH2C12 and the inorganics filtered off.
Evaporation of the filtrate in vacuo afforded the title compound as a yellow solid (1.8g,
74%). i H NMR (250MHz, CDC13) δ(ppm): 8.46 (d, IH), 7.72 (s, IH), 6.96 (s. IH), 6.77 (d, IH),
4.14 (br s, IH), 3.68 (t, 2H), 323 (t, 2H). 3J9 (br s, 4H), 2.68 (br s, 4H). 2.41 (s, 3H). MS: m/z = 269 (MH+)
Description 43 N-[Quinolin-6-yl]acetamide (D43)
To a solution of 6-aminoquinoline (5.0g, 35mmol) in CH C12 (200ml) at 0°C was added acetic anhydride (3.5ml, 37mmol) and the mixture stirred whilst warming to room temperature for 16 hours. The mixture was washed with aqueous 10% Na2CO3 solution (2x), dried (Na2SO4) and evaporated in vacuo to a white solid (5.7g, 88%). Η NMR (250 MHz, d6DMSO) δ (ppm): 8.78 (m, IH), 838 (d, IH), 8.28 (d, IH), 7.97 (d, IH), 7.78 (dd, IH), 7.47 (dd, IH), 3.37 (s, IH), 2.13 (s, 3H).
Description 44 N-[l,2 ,4-Tetrahydroquinolin-6-yl]acetamide (D44)
A solution of N-[quinolin-6-yl]acetamide (D43, 5.0g, 26.9mmol) in ethanol was hydrogenated over PtO (0.5g) at 50°C and 50 psi (344.8KPa) for 72 hours. The catalyst was removed by filtering through Celite (Diatomaceous Earth) and the filtrate evaporated in vacuo to a pale yellow oil (52g. 100%). i H NMR (250MHz, CDCI3) δ(ppm): 7.09 (m, 2H), 6.97 (dd, IH), 6.41 (d, I H), 327 (t, 2H), 2.99 (br s, IH). 2.73 (t, 2H), 2.02 (s, 3H), 1.92 (m, 2H).
Description 45 N-[l-BenzyI-l,23.4-tetrahydroquinolin-6-yI]acetamide (D45)
To a stirred solution of N-[1.23,4-tetrahydroquinolin-6-yl]acetamide (D44, 5.0g, 26mmol) in acetone (100ml) was added K2CO3 (4.4g, 32mmol) followed by dropwise addition of benzyl bromide (3.8ml. 32mmol) over 3 minutes. The mixture was stirred at room temp, for 16 hours and then heated at reflux for 2 hours. On cooling, the mixture was filtered to remove inorganics and the filtrate evaporated to an orange solid (7.7g, 100%). 1H NMR (250MHZ, CDCI3) δ(ppm): 720-738 (m, 5H), 7J 5 (d, IH), 6.93 (m, 2H), 6.42 (d, IH), 4.45 (s, 2H), 3.34 (t, 2H). 2.80 (t. 2H . 2.1 1 (s, 3H), 1.97 (m. 2H). Description 46 6-Amino-l-benzyl-l,2,3,4-tetrahydroquinoline (D46)
A solution of N-[l -benzyl- 1 ,2, 3,4-tetrahydroquinoiin-6-yl]acetamide (D45, 6.6g, 23.5mmol) in ethanol (100ml) and 2N NaOH solution (160ml) was heated at reflux for 16 hours. On cooling, the mixture was evaporated in vacuo and the residue extracted with CH2C12 (2x), the organics dried ( a2SO4) and evaporated to a brown oil (5.9g, 100%). i H NMR (250MHz. CDC13) δ(ppm): 720-737 (m, 5H). 6.44 (d, IH), 6.40 (m, 2H), 438 (s, 2H), 3.23-327 (m. 4H), 2.75 (t, 2H), 1.98 (m, 2H).
Description 47
Diethyl [l-benzyl-l,23,4-tetrahydroquinolin-6-yIamino]methylenemalonate (D47)
The title compound was prepared from 6-amino-l -benzyl- 12,3 ,4-tetrahydroquinoline (D46,
5.6g, 23.5mmol) following a similar procedure to Description 37 (9J8g, 96%).
Η NMR (250 MHz. CDC13) δ (ppm): 10.92 (d, IH), 8.38 (d, IH), 7.22-738 (m, 5H), 6.74-
6.81 (m, 2H), 6.45 (d, IH), 4.48 (s, 2H), 4.16-4.32 (m, 4H), 3.39 (t, 2H), 2.82 (t, 2H), 2.03
(m, 2H), 125-1.40 (m, 6H).
Description 48
Ethyl l-benzyl-9-chloro-l,2,3.4-tetrahydroquinoIin-8-yIcarboxylate (D48)
The title compound was prepared from diethyl 1 -benzyl- 1,2.3, 4-tetrahydroquinolin-6- ylaminojmethylenemalonate (D47, 9Jg, 223mmol) following a similar procedure to Description 38 (3J 8g. 37%).
Η NMR (250 MHz. CDC13) δ (ppm): 8.79 (s, IH), 7.68 (s. IH), 728-737 (m, 5H), 7.11 (s, IH), 4.67 (s, 2H), 4.43 (q, 2H), 3.55 (t, 2H), 3.06 (t, 2H), 2.09 (m, 2H), 1.42 (t, 3H).
Description 49
Ethyl l-benzyl-9-(4-methylpiperazin-l-yI)-l,2 .4-tetrahydropyrido[2,3-g]quinolin-8- ylcarboxylate (D49)
The title compound was prepared from ethyl 1 -benzyl-9-chloro- 1.2,3, 4-tetrahydroquinolin-8- ylcarboxylate (D48. 3Jg, 8J4mmol) following a similar procedure to Description 39 (4.2g,
100%).
Η NMR (250 MHz. CDC13) δ (ppm): 8.52 (s, IH). 7.64 (s, I H), 723-736 (m, 5H). 6.78 (s,
IH), 4.67 (s, 2H). 4.38 (q, 2H), 3.57 (t, 2H), 3.08 (m. 6H), 2.18 (s, 3H), 2.07-2.18 (m, 6H).
1.38 (t, 3H). Description 50 l-Benzyl-9-(4-methylpiperazin-l-yl)-l,2 ,4-tetrahydropyrido[2 -g]quinolin-8- ylcarboxylic acid (D50)
The title compound was prepared from ethyl l-benzyl-9-(4-methylpiperazin-l-yl)-l,2,3,4- tetrahydropyrido[2.3-g]quinolin-8-ylcarboxylate (D49, 3.62g, 8J4mmol) following a similar procedure to Description 40 (2.96g, 87%).
'H NMR (250 MHz, d6DMSO) δ (ppm): 8.33 (s, IH), 7.52 (s, IH), 721-738 (m, 5H), 6.63 (s, IH), 4.70 (s, 2H), 3.59 (t, 2H), 3.10 (br s. 4H), 3.00 (t. 2H), 2,45 (br s, 4H - partially obscured), 2.39 (s, 3H), 2.04 (m. 2H). Acid proton not observed.
Description 51 l-Benzyl-9-(4-methylpiperazin-l-yI)-l,2 ι4-tetrahydropyrido[2,3-g]quinoline (D51)
The title compound was prepared from l-benzyl-9-(4-methylpiperazin-l-yl)- 1,2,3,4- tetrahydropyrido[2,3-g]quinolin-8-ylcarboxylic acid (D50, 2.5g, ό.Ommol) following a similar procedure to Description 41 (lJg, 76%).
'H NMR (250 MHz, CDC13) δ (ppm): 838 (d, IH), 7.64 (s, IH), 721-736 (m, 5H), 6.63 (d,
IH), 6.58 (s, IH), 4.64 (s, 2H), 3.58 (t, 2H), 3.05 (t, 2H), 2.91 (br s, 4H), 2.28 (br s, 4H), 2.27
(s, 3H), 2J2 (m, 2H).
Description 52
9-(4-lVIethylpiperazin-l-yl)-l,2,3,4-tetrahydropyrido[2,3-g]q inoline (D52) The title compound was prepared from l-benzyl-9-(4-methylpiperazin-l-yl)- 1,2,3,4- tetrahydropyrido[2,3-g]quinoline (D51. 1.7g, 4.56mmol) following a similar procedure to Description 42 (1.5g, 100%)
Η NMR (250 MHz, CDC13) δ (ppm): 8.41 (d, IH), 7.63 (s, IH), 6.84 (s. IH), 6.70 (d, IH), 4.31 (br s, IH), 3.40 (t, 2H), 3.18 (br s, 4H), 2.99 (t, 2H), 2.67 (br s, 4H). 2.40 (s, 3H), 2.00 (m, 2H).
Description 53 N-[2-Bromophenyl]glyoxamide oxime (D53)
A stirred solution of chloral hydrate (26.5g, OJόmol) in water (350ml) was treated with sodium sulphate (350g, 2.5mol) followed by a solution of 2-bromoaniline (25g. 0J45mol) in a mixture of water (220ml) and cone. HCl acid (13ml). The resulting mixture was treated with a solution of hydroxylamine hydrochloride (313g, 0.45mol) in water (140ml) and then heated up to reflux over 1 hour and held at that temperature for 3 minutes, then cooled in an ice/water bath to room temperature. Brown pellets of the title compound were formed in the mixture. These were filtered off, washed thoroughly with water and dried under vacuum (292g, 83%).
Η NMR (250MHz. CDC13) δ (ppm): 8.93 (br s, IH), 8.41 (dd. IH). 8.06 (br s. IH). 7.60 (s, IH), 7.56 (dd, IH), 7.34 (dt, I H), 7.01 (dt, IH).
Description 54 7-Bromoisatin (D54)
Finely ground N-[2-bromophenyl]glyoxamide oxime (D53, 292g, 0J2mol) was added portionwise to well stirred cone. H2SO4 (64ml) at 50°C maintaining an internal temperature of 50-70°C during the addition. The mixture was then heated to 80-85°C for 10 minutes, cooled to room temperature and poured onto crushed ice (600g) with stirring. A red/brown precipitate ofthe title compound formed. This was filtered off, washed with water and dried in a vacuum oven (14.8g, 55%).
'H NMR (250MHz, CDC13) δ (ppm): 7.88 (br s, IH), 7.71 (dd, IH), 7.59 (d, IH), 7.06 (t, IH).
Description 55 8-Bromoquinoiine-2,4-dicarboxyiic acid (D55)
Potassium hydroxide (31.5g, 0.56mol) was dissolved in water (95ml) with stirring, and the hot solution treated with 7-bromoisatin (D54, 14.8g, 0.065mol) followed by pyruvic acid (7.9ml, 0J2mol). The resulting mixture was stirred at room temperature for 1 hour, then heated at reflux for 1.5 hours. The mixture was allowed to cool, diluted with water (250ml), treated with ethyl acetate (100ml) and stirred vigorously for 10 minutes. The aqueous layer was separated off and added dropwise to cooled, well stirred, cone. HCl acid (25ml). Additional concentrated HCl acid was added to adjust the pH to 1 and the solid was filtered off, washed with water and dried in a vacuum oven to afford the title compound as a tan coloured solid (143g, 74%).
'H NMR (250 MHz. d6DMSO) δ (ppm): 8J9 (dd. IH), 8.50 (s, IH), 8.32 (dd, 1H0, 7.74 (dd, 1 H). Acid protons not discernible.
Description 56 8-Bromoquinolin-4-yIcarboxylic acid (D56)
50 - A stirred suspension of 8-bromoquinoline-2,4-dicarboxylic acid (D55, 14.2g, 0.048mol) in nitrobenzene (60ml) was heated under reflux for 2 hours, then cooled to room temperature and treated with hexane (90ml). The precipitate was filtered off. washed with hexane and dried in a vacuum oven to afford the title compound as a grey/ brown solid (1 1.5g, 95%). 'H NMR (250 MHz. d6DMSO) δ (ppm): 9.14 (d, IH), 8.70 (dd, IH), 8.24 (dd, IH), 8.00 (d. IH), 7.63 (dd, IH). Acid proton not discernible.
Description 57
8-Bromoquinoiin-4-yl isocyanate (D57)
The title compound was prepared from 8-bromoquinolin-4-ylcarboxylic acid (D56) using a similar procedure to Description 28. The isocyanate was not isolated, but used in the next step as its toluene solution.
Description 58
8-(2-FIuorophenyl)quinolin-4-ylcarboxylic acid (D58)
The title compound was prepared from 8-bromoquinolin-4-ylcarboxylic acid (D56) and 2- fluorophenylboronic acid using a similar procedure to Description 3 as a pale brown solid
(57%).
Η NMR (250 MHz, d6DMSO) δ (ppm): 14.07 (br s, IH), 9.09 (d, IH), 8.85 (m, IH), 8.04
(d, IH), 7.93-7.87 (m, 2H), 7.64-7.55 (m, 2H), 7.44-737 (m, 2H).
Description 59
8-(2-FluorophenyI)quinolin-4-yl isocyanate (D59)
The title compound was prepared from 8-(2-fluorophenyl)quinolin-4-ylcarboxylic acid (D58) using a similar procedure to Description 28. The isocyanate was not isolated, but used in the next step as its toluene solution.
Description 60 8-(2-Methoxyphenyl)quinolin-4-ylcarboxylic acid (D60)
The title compound was prepared from 8-bromoquinolin-4-ylcarboxylic acid (D56) and 2- methoxyphenylboronic acid using a similar procedure to Description 3 as a pale brown solid
(69%).
Η NMR (250 MHz, d6DMSO) δ (ppm): 13.89 (br s, IH). 8.92 (d, IH), 8.65 (dd, IH), 7.88
(d, IH), 7.78-7.67 (m. 2H), 7.40 (dt. IH), 7.22 (dd. IH). 7.1 1 (d. IH), 7.03 (t, IH), 3.60 (s.
3H). Description 61
8-(2-Methoxyphenyl)quinolin-4-y_ isocyanate (D61)
The title compound was prepared from 8-(2-methoxyphenyl)quinolin-4-ylcarboxylic acid (D60) using a similar procedure to Description 28. The isocyanate was not isolated, but used in the next step as its toluene solution.
Description 62 6-Nitro-4-(piperazin-l-yl)quinoIine (D62)
A solution of 4-chloro-6-nitroquinoline (J. Org. Chem. 1944. 9, 302) (5.0g, 24mmol) and piperazine (83g, 96mmol) in toluene (100ml) was heated to reflux for 24 hours under argon. The solution was concentrated in vacuo and the residue was dissolved in dichloromethane (150ml), washed with water (3 x 200ml), dried (Na2SO4) an°l concentrated to give the title compound as an orange solid (6.0g, 98%). MS: m z = 259 (MH+).
Description 63 4-(4-/ert-Butoxycarbonylpiperazin-l-yl)-6-nitroquinoline (D63)
Water (80ml) was added over 5 min to a stirred solution of 6-nitro-4-(piperazin-l- yl)quinoline (D62, 6.0g, 23.4mmol) in tetrahydrofuran (80ml) at room temperature. To this solution was added a solution of di-tert-butyldicarbonate (5.1g, 23.4mmol) in tetrahydrofuran (20ml) over 0.5 hours, followed by the portionwise addition of potassium carbonate (3.4g, 24.6mmol). The mixture was stirred for 3 days and then the organic solvent was evaporated in vacuo and the remaining aqueous residue was extracted with dichloromethane (4 x 150ml). The extract was dried (Na2SO4) and concentrated to an oil which crystallized in diethyl ether/hexane (1 : 1) to give the title compound (7.7g, 92%). MS: m z = 359 (MH+).
Description 64 6-Amino-4-(4-/ert-butoxycarbonyIpiperazin-l-yl)quinoline (D64)
4-(4-tert-Butoxycarbonylpiperazin- 1 -yl)-6-nitroquinoline (D63, 7.7g, 21.5mmol) was hydrogenated as described in Description 2 to give the title compound as a yellow solid (7J , 100%). MS: m/z = 329 (MH+).
Description 65
N-[5-Bromonaphth-l-yl]-N'-[4-(4-tert-butoxycarbonyIpiperazin-l-yl)quinolin-6-yl]-urea
(D65)
- j 2 - The title compound was prepared from 5-bromonaphth-l -yl isocyanate (D25) and 6-amιno-4-
(4-tert-butoxycarbonylpiperazin-l-yl)quinoline (D64) using a similar procedure to Example
27 (71%).
Η NMR (250MHz. CDC1,) δ (ppm): 8.55 (d. IH), 8.41 (d. I H), 8.35 (br s. IH). 7.97 (d. I H),
7.85 (br s, IH). 7.73-7.82 (m. 2H). 7.63 (d, IH), 7.42 (t, I H). 7.14-7.29 (m, 2H), 7.03 (t. I H),
6J0 (d, IH), 3.64 (br m, 4H). 3.09 (br m, 4H), 1.44 (s, 9H). MH* 576/578.
Example 1
N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[4-(4-methylpiperazin-l-yl)quinoIin-6-yI]-urea
(El)
3-Chloro-4-(pyridin-4-yl)aniline (D4, 204mg, lmmol) in CH2C1 (10ml) and triethylamine (lOlmg, lmmol) was added to a solution of triphosgene (97mg, 033mmol) in CH2C12 over a period of 2 minutes and the reaction stirred under argon for 1 hour. The reaction was then treated with 6-amino-4-(4-methylpiperazin-l-yl)quinoline (D2, 232mg, lmmol) and the reaction stirred under argon for 48 hours. The reaction was then washed with saturated aqueous K CO3 solution, dried (Na SO4)and concentrated in vacuo to a gum. The gum was chromatographed on silica in a gradient of 5-20%) MeOH in CH C12. Elution with 20% MeOH in CH C12 gave the title compound (20mg, 4%), m.p. 151-153°C. 1H NMR (250MHZ. CDCI3) δ (ppm): 9.1 (s, IH), 8.95 (s, IH), 8.65 (d, 2H), 8.55 (d, IH), 8.5 (s, IH), 7.8 (d, IH), 7.6 (s, IH), 7.45 (d, IH), 7.3 (d, 2H), 7.2 (d, 2H), 6.8 (d, IH), 3.25 (br s, 4H), 2.65 (br s, 4H), 2.35 (s, 3H).
Example 2
N-^^-Methylpiperazin-l-y quinolin-ό-yll-N'-^^pyridin^-y naphth-l-ylj-urea (E2) The title compound was prepared from 4-(pyridin-4-yl)-l-naphthylamine (D5) and 6-amino- 4-(4-methylpiperazin-l-yl)quinoline (D2) following a similar procedure to Example 1 to give the title compound as a yellow powder from ether (38%), m.p. 165 - 170°C. Η NMR (250 MHz. CDC13) δ (ppm): 8.95 (s, IH), 8.7 - 8.5 (m, 4H), 8.25 (s, IH), 8.0 (d, IH), 7.9 (d, IH). 7.8 (d, IH), 7.7 (d, IH), 7.3 - 7.1 (m, 6H), 6.75 (d, IH), 3.2 (br s, 4H). 2.6 (br s. 4H), 2.2 (s. 3H).
Example 3
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yI]-N'-[5-(pyridin-4-yl)naphth-l-yll-urea (E3) The title compound was prepared from 5-(pyridin-4-yl)-l-naphthylamine (D6) and 6-amino- 4-(4-methylpiperazin-l-yl)quinoline (D2) following a similar procedure to Example 1 as needles from ether (33%), m.p. 164 - 166°C.
'H NMR (250 MHz. CDC13) δ (ppm): 8.8 (s, IH). 8.65 (d, 2H), 8.55 (m, 2H). 8.15 (s, IH), 8.0 (d. IH), 7.8 (t, 2H). 7.5 (d. IH). 7.35 - 7.2 (m, 5H), 7.1 (d, I H). 6.7 (d, IH), 3.2 (br s. 4H). 2.6 (br s, 4H), 2.2 (s, 3H).
Example 4 N-[4-(4-Methyipiperazin-l-yl)quinolin-6-yl]-N'-[quinolin-6-yI]-urea (E4)
The title compound was prepared from 6-aminoquinoline and 6-amino-4-(4-methypiperazin- l-yl)quinoline (D2) following a similar procedure to Example 1 as a yellow powder from ether (1 1%), m.p. 240 - 250°C (dec).
Η NMR (250 MHz, CDCIJCD3OD (1 : 1)) δ (ppm): 8J5 (s, IH). 8.5 (d, 2H). 83 (s, IH). 8.2 (d, IH), 8.05 - 7.85 (m, 2H), 7.55 (d, IH), 7.5 - 7.3 (m, 4H). 6.85 (s, IH), 3.35 (br s, 4H),2.85 (br s, 4H), 2.45 (s, 3H).
Example 5 4-Bromo-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]naphth-l-ylacetamide (E5)
4-Bromonaphth-l-ylacetic acid (J. Org. Chem. 1951, 16, 1588) (0.58g, 2.2 mmol) in CH,C12 (50ml) was treated with oxalyl chloride (830mg, 6.6mmol) at room temperature with continuous stirring for 2 hours. The reaction was then concentrated in vacuo and azeotroped with toluene to remove excess oxalyl chloride. The acid chloride was dissolved in dry CH2C12 .and treated with 6-amino-4-(4-methylpiperazin-l-yl)quinoline (D2, 0.5g, 2.192 mmol) and triethylamine (224mg, 2.2 mmol) with continuous stirring at room temperature for 18 hours. The reaction was then washed with saturated aqueous potassium carbonate solution, dried (Na2SO4) and concentrated in vacuo to a gum (760mg. 70%). Η NMR (250 MHz, CDC13) δ (ppm): 8.6 (d, IH), 8.55 (s, IH), 8.35 (d, I H), 8.0 (d, IH), 7.85 - 7.75 (dd. 2H), 1.1 - 7.6 (m, 3H), 735 (d, IH), 7.1 (d, IH). 6J5 (d, I H), 4.2 (s, 2H), 3.25 (br s. 4H), 2.1 (br s, 4H). 2.4 (s, 3H).
Example 6 5-Bromo-N-[4-(4-methyIpiperazin-l-yl)quinolin-6-yl]naphth-l-ylacetamide (E6).
The title compound was prepared from 5-bromonaphth-l-ylacetic acid (Bull. Soc. Chim. Fr. 1968. 7. 2957) and 6-amino-4-(4-methylpiperazin-l-yl)quinoline (D2) following a similar procedure to Example 5 (48%). 'H NMR (250 MHz. CDC13) δ (ppm): 8.6 (d, IH), 8.5 (s, IH). 83 (d. IH), 7.85 (s, IH), 7.8 (d, IH), 7.65 - 7.5 ( . 2H), 7.45 (s, IH), 1Λ (d, IH). 7.35 (d. I H). 7.1 (dd. IH), 6.8 (d, IH), 4.25 (s, 2H), 325 (br s, 4H), 2.75 (br s. 4H), 2.4 (s, 3H).
Example 7
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-4-(pyridin-4-yl)naphth-l-ylacetamide (E7) The title compound was prepared from 4-bromo-N-[4-(4-methylpiperazin-l-yl)quinolin-6- yl]naphth-l -ylacetamide (E5) and pyridin-4-ylboronic acid using a similar procedure to Description 3 (56%).
Η NMR (250 MHz. CDC1J δ (ppm): 8.7 (d, 2H), 8.6 (m, 2H), 8.15 (d, IH), 8.05 (s, IH), 7.9 (d, IH), 7.85 (d, IH), 7.65 - 7.4 (m, 6H), 7.2 (dd, IH), 6.8 (d, IH), 4.3 (s, 2H), 3.25 (br s, 4H), 2.7 (br s, 4H), 2.4 (s, 3H).
Example 8
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-5-(pyridin-4-yi)naphth-l-ylacetamide (E8) The title compound was prepared from 5-bromo-N-[4-(4-methylpiperazin-l-yl)quinolin-6- yl]naphth-l -ylacetamide (E6) following a similar procedure to Description 3 as a yellow foam (54%).
Η NMR (250 MHz. CDC13) δ (ppm): 8.75 (d, 2H), 8.6 (d, 2H), 8.15 (d, IH), 8.05 (s, IH), 7.85 (dd, 2H), 7.65 - 7.35 (m, 6H), 7.15 (dd, IH), 6.8 (d, IH), 4.3 (s, 2H), 3.25 (br s, 4H), 2.7 (br s, 4H), 2.4 (s, 3H).
Example 9
N-[4-(4-MethyIpiperazin-l-yl)quinolin-6-y-]-N'-[4-(pyridin-4-yI)-3- trifluoromethylphenyl]-urea (E9)
The title compound was prepared from 4-(pyridin-4-yl)-3-trifluoromethylaniline (D8) and 6- amino-4-(4-methylpiperazin- 1 -yl)quinoline (D2) following a similar procedure to Example 1 as a yellow powder (47%).
'H NMR (250 MHz. CDC13) δ (ppm): 93 (s. IH), 9,2 (s, IH), 8.6 (d, 2H), 8.55 (d, 2H), 7.8 (m, 2H), 7.7 (d, IH), 7.2 (d, 2H), 7.1 (m, 2H), 6.8 (d, IH), 3.3 (br s, 4H), 2.65 (br s. 4H), 2.35 (s, 3H).
Example 10
N-[3-Cyano-4-(pyridin-4-yl)phenyI]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yll-urea
(E10) The title compound was prepared from 3-cyano-4-(pyridin-4-yl)aniline (D10) and 6-amino-4- (4-methylpiperazin-l-yl)quinoline (D2) following a similar procedure to Example 1 (35%). 'H NMR (250 MHz. CDCL) δ (ppm): 9.3 (br s, IH), 9.1 (br s. I H). 8.7 (d. 2H), 8.6 (d, I H), 8.5 (s. IH), 7.9 (s, IH), 7.85 (d. IH). 7.45 (d. 2H), 7.35 (d. IH), 7.2 (d, IH), 7.1 (s, IH), 6.85 (m, I H), 3.25 (m. 4H), 2.7 (m. 4H). 2.4 (s, 3H).
Example 11 N-{4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[quinolin-5-yl]-urea (Ell)
The title compound was prepared from 5-aminoquinoline and 6-amino-4-(4-methylpiperazin- l-yl)quinoline (D2) following a similar procedure to Example 1 as a yellow solid (33%). Η NMR (250 MHz, d6DMSO) δ (ppm): 9.4 (s, IH), 9.05 (s, IH), 8.95 (d, IH), 8.6 (d, IH), 8.55 (d, IH), 83 (d, IH), 8.05 (dd, IH), 7.9 (d, IH), 7.8-7.7 (m. 3H), 7.6 (dd. IH). 6.9 (d, I H), 3.2 (m, 4H), 2.65 (m. 4H), 2.3 (s, 3H).
Example 12 N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yI]-N'-[quinolin-8-yl]-urea (E12)
The title compound was prepared from 8-aminoquinoline and 6-amino-4-(4-methylpiperazin- l-yl)quinoline (D2) following a similar procedure to Example 1 (60%). Η NMR (250 MHz, CDC13) δ (ppm): 9.7 (s, IH), 8.7 (d, IH), 8.6 (d, IH), 8.4 (s, IH), 825 (m, IH), 8.0 (d, IH), 7.95 (d. IH), 7.7 (d, IH), 7.5 (t, IH), 7.35 (s, IH), 7.31 (d, IH), 7.25 (dd, IH), 7.01 (d, IH) 32(m. 4H), 2.6(m, 4H), 2.3 (s, 3H).
Example 13
N-[4-(4-Methyipiperazin-l-yi)quinolin-6-yl]-N'-[quinolin-3-yl]-urea (E13)
The title compound was prepared from 3-aminoquinoline and 6-amino-4-(4-methylpiperazin-
1 -yl)quinoline (D2) following a similar procedure to Example 1 (8.5%o).
'H NMR (250 MHz, CDC13) δ (ppm): 9.4 (s, IH), 9.25 (s, IH). 875 (s, IH), 8.5 (s, IH), 8.4
(d, IH), 7.9 (d, IH), 7.8 (d, IH), 7.65 (d, IH), 7.55-7.45 (m. 4H), 6.7 (d, I H), 3.25 (m, 4H),
2.6 (m, 4H), 2.3 (s, 3H).
Example 14 2 -Dichloro-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]phenyiacetamide (E14)
The title compound was prepared from 2,3-dichlorophenylacetic acid (D13) and 6-amino-4- (4-methylpiperazin-l-yl)quinoline (D2) following a similar procedure to Example 5 to give a solid, which was crystallised from acetone (76%). Η NMR (250 MHz. CDC13) δ (ppm): 8.65 (d. IH), 8.55 (s, IH), 7.95 (d. IH), 7.75 (s, IH), 7.45 (d. IH), 1.4 (d, 2H), 7.3 (t. IH), 6.8 (d. IH), 3.9 (s, 2H). 3.35 (m. 4H). 2.7 (m, 4H), 2.4 (s. 3H).
Example 15 5-(4-AcetyIphenyl)-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]naphth-l-yIacetamide
(E15)
The title compound was prepared from 5-bromo-N-[4-(4-methylpiperazin-l-yl)quinolin-6- yl]naphth-l -ylacetamide (E6) and 4-acetylphenylboronic acid following a similar procedure to Description 3 (35%).
'H NMR (250 MHz, CDC13) δ (ppm): 8.6 (s, 2H), 8.3 (s, IH), 8.05 (m, 3H), 7.8(t, 2H), 7.7-
7.35 (m, 6H), 725 (m, IH), 6.8 (d, IH), 4.25 (s, 2H), 325 (br s, 4H), 2.65 (br s, 7H), 2.3 (s,
3H).
Example 16 N-[4-(4-MethyIpiperazin-l-yl)quinolin-6-yl]-N'-[quinoIin-4-yl]-urea (E16)
The title compound was prepared from 4-aminoquinoline and 6-amino-4-(4-methylpiperazin- l-yl)quinoline (D2) following a similar procedure to Example 1 (6%). Η NMR (250 MHz, CDC13) δ (ppm): 9.85 (s, IH), 8.75 (d, IH), 8.55 (s, IH), 8.4 (m, IH), 8.35 (d. IH), 7.95 (d, 2H), 7.8 (d, IH), 7.5 (m, 2H), 7.1 (m, IH), 6.75 (d, IH), 6.05 (s, IH), 3.25 (br s, 4H). 2.65 (br s, 4H). 2.3 (s, 3H).
Example 17 N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[4-(l-methylpiperidin-4-yl)quinolin-6-yI]-urea
(E17)
The title compound was prepared from 3-chloro-4-(pyridin-4-yl)aniline (D4) and 6-amino-4-
(l-methylpiperidin-4-yl)quinoline (D16) following a similar procedure to Example 1. The crude product was purified by chromatography on silica gel eluting with a gradient of 50-
70% methanol in dichloromethane. The main slow running fraction was collected to give the title compound as a colourless powder (7%).
Η NMR (250MHz, CDC13) δ (ppm): 8.9 (s, IH), 8.8 (s, IH). 8.7 (d, IH). 8.6 (m, 3H), 7.9 (d,
IH), 7.6 (d, IH). 7.4 (dd, IH). 73 (d, 2H), 7.25 (d, 2H), 7.15 (d, I H), 3.3-2.95 (m, 3H), 3.0
(s, 3H), 23-2.1 (m. 2H), 2.0- 1.8 (m, 4H). MH+ 472.
Example 18 N-[3-MethyI-4-(6-methylpyridin-2-yl)phenyIl-i\'-[4-(4-methylpiperazin-l-yI)quinolin-6- yl]-urea (E18)
The title compound was prepared from 3-methyl-4-(6-methylpyridin-2-yl)aniline (D18) and
6-amino-4-(4-methylpiperazin- l-yl)quinoline (D2) using a similar procedure to Example 1
(24%).
Η NMR (250MHz. d6DMSO) δ (ppm): 9.03 (s. IH). 8.78 (s. IH), 8.50 (d, IH), 8.17 (d. IH),
7.84 (d, IH), 7.74-7.64 (m. 2H), 7.47-720 (m. 4H), 7J4 (d. IH), 6.88 (d, IH), 3.14 (br s.
4H), 2,60 (br s. 4H). 2.47 (s. 3H), 2.31 (s, 3H), 227 (s, 3H).
Example 19
N-[4-(2,6-Dimethylpyridin-4-yl)-3-methylphenyl]-N'-[4-(4-methylpiperazin-l- yl)quinoiin-6-yI]-urea (E19)
The title compound was prepared from 4-(2.6-dimethylpyridin-4-yl)-3-methylaniline (D19) and 6-amino-4-(4-methylpiperazin-l-yl)quinoline (D2) using a similar procedure to Example 1 (55%).
Η NMR (250MHZ, CDC13) δ (ppm): 8.99 (br s, IH), 8.57 (d, IH), 8.53 (s, 2H), 7.81 (d, IH), 732-7.24 (m, 2H), 7.1 1 (dd, IH), 7.05 (d, IH), 6.78 (br s, 3H), 3.24 (br s. 4H), 2.63 (br s, 4H), 2.51 (s, 6H), 2.30 (s, 3H), 2.13 (s, 3H).
Example 20 N-[5-Cyanonaphth-l-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea (E20)
The title compound was prepared from 5-cyano-l-naphthylamine (EP 456090) and 6-amino- 4-(4-methylpiperazin-l-yl)quinoline (D2) using a similar procedure to Example 1 as a pale buff solid (50%).
Η NMR (250MHZ, CDC13) δ (ppm): 8.70 (s, IH), 8.55 (d, IH), 8.50 (d, IH), 8.1 1 (s, IH), 8.04 (d, IH), 7.93 (d, IH). 7.83 (q, IH), 7.72 (d, IH), 7.50 (t, IH), 7.19 (t, IH), 7.12 (dd. 2H), 6.77 (d, IH), 3.22 (s, 4H), 2.60 (s, 4H), 2.26 (s, 3H).
Example 21
N-[5-(5-Methyl-lJ,4-oxadiazol-3-yl)naphth-l-yl]-N'-[4-(4-methyIpiperazin-l- yI)quinoIin-6-yl]-urea (E21)
The title compound was prepared from 5-(5-methyl-1.2,4-oxadiazol-3-yl)-l-naphthylamine
(D22) and 6-amino-4-(4-methylpiperazin-l-yl)quinoline (D2) using a similar procedure to
Example 1. The hydrochloride salt was isolated as a green powder (34%). Η NMR (HCl salt) (250MHz. d6DMSO) δ (ppm): 11.36 (s, IH), 1 1.05 (s. I H). 9.80 (s, IH), 8.76 (d. IH), 8.68 (d, IH), 8.59 (s, IH). 8.18 (q, 3H), 7.96 (d, IH), 7.76-7.64 (m. 2H), 7.33 (d. I H). 4.22 (br s. 2H), 3.62 (br s. 4H). 2.90 (s. 3H), 2.75 (s, 3H). 2H obscurred by H O signal.
Example 22 N-[4-(4--VIethyIpiperazin-l-yl)quinoIin-6-yI]-N'-[5-(pyrimidin-2-yIoxy)naphth-l-yl]-urea
(E22)
The title compound was prepared from 5-(pyrimidin-2-yloxy)-l-naphthylamine (D23) and 6- amino-4-(4-methylpiperazin-l -yl)quinoline (D2) using a similar procedure to Example 1 as a pale yellow solid (10%).
'H NMR (250MHz. d6DMSO) δ (ppm): 9.41 (s, IH), 8.91 (s, IH), 8.63 (d. 2H), 8.54 (d, IH),
8.32 (d, IH), 8.08 (d, 1H0, 7.93 (dd. IH). 7.88 (d, IH), 1.16-1.62 (m, 2H), 7.50 (m, 2H), 7.41
(d, IH), 7.28 (t, IH), 6.92 (d, IH), 3J5 (br s, 4H), 2.64 (br s, 4H), 2.30 (s. 3H).
Example 23
N-[5-Acetylnaphth-l-yl]-N*-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea (E23) The title compound was prepared from 5-acetyl-l-naphthylamine (D24) and 6-amino-4-(4- methylpiperazin-l-yl)quinoline (D2) using a similar procedure to Example 1. The hydrochloride salt was isolated as a yellow/green solid (72%).
Η NMR (HCl salt) (250MHz, d6DMSO) δ (ppm): 10.77 (s, IH), 9.62 (s. IH). 8.70 (d, IH), 8.63 (d, IH), 8.53 (d, IH), 8.27 (d, IH), 8.10 (m, 4H), 7.87 (dd, IH), 7.69-7.57 (m, 2H), 7.23 (d, IH). 3.50 (br s, 4H), 337 (br s. 4H). 2.89 (s, 3H), 2.74 (s, 3H).
Example 24 N-[5-Bromonaphth-l-yl]-N'-[4-(4-methyIpiperazin-l-yl)quinolin-6-yl]-urea (E24)
The title compound was prepared from 5-bromonaphth-l-yl isocyanate (D25) and 6-amino-4-
(4-methylpiperazin-l-yl)quinoline (D2) using a similar procedure to that described for
Example 27. The free base was converted to monohydrochloride salt as a yellow solid from acetone.
'H NMR (HCl salt) (250MHz. d6DMSO) δ (ppm): 1 1.19 (br s, IH). 1 1.03 (s. IH), 9.76 (s,
IH). 8.90 (d, IH). 8.69 (s, IH). 8.59 (d, IH). 8.28-823 (m. 2H). 8.07-8.03 (m. 3H), 7.80 (t,
IH), 7.61 (t, IH), 7.46 (d, IH), 436 (br d. 2H). 3.82-3.72 (br m, 6H), 3.10 (s, 3H).
Example 25 N-[5-(6-Methylpyridin-2-yl)naphth-l-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yI]- urea (E25)
The title compound was prepared from 5-(6-methylpyridin-2-yl)naphth-l -yl isocyanate (D28) and 6-amιno-4-(4-methylpiperazin-l-yl)quinoline (D2) using a similar procedure to Example 27 (24%).
Η NMR (250MHZ, d6DMSO) δ (ppm): 9.47 (s, IH), 8.96 (s. IH), 8.55 (d, IH). 8.34 (d, IH), 8.27 (d, IH), 8.01 (d. IH), 7.95-7.82 (m, 2H), 7.78-7.64 (m, 3H), 7.60 (d. IH), 7.55-7.40 (m. 2H), 7.34 (d, IH). 6.93 (d, IH), 3.18 (br s, 4H), 2.64 (br s. 4H), 2.57 (s, 3H), 2.30 (s. 3H).
Example 26
N-[5-(2-Methyipyridin-5-yl)naphth-l-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]- urea (E26)
The title compound was prepared from 5-(2-methylpyridin-5-yl)naphth-l-yl isocyanate (D30) and 6-amino-4-(4-methylpiperazin-l-yl)quinoline (D2) using a similar procedure to Example 27 (45%).
'H NMR (250MHZ, CDC13) δ (ppm): 8.96 (s, IH), 8.58-8.51 (m, 2H), 8.46 (d, IH), 8.28 (s, IH), 7.92 (d, IH), 7.80-7.70 (m, 2H), 7.52-7.43 (m, 2H), 730-7.00 (m, 5H), 6.70 (d, IH), 3.15 (br s, 4H), 2.62 (s, 3H), 2.14 (s, 3H).
Example 27
N-[5-(2-Methylpyridin-3-yl)naphth-l-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yI]- urea (E27)
A solution of 5-(2-methylpyridin-3-yl)naphth-l-yl isocyanate (D32, 1.2 mmol) in toluene (13ml) was added to a stirred solution of 6-amino-4-(4-methylpiperazin-l-yl)quinoline (D2, 210mg, 0.83 mmol) and maintained at room temperatuire for 48 hours. The mixture was concentrated in vacuo .and the residue purified by column chromatography on basic alumina eluting with 0-10% methanol/ethyl acetate to afford the title compound as a pale yellow foam (370mg, 87%>). This was converted to its hydrochloride salt as a pale yellow solid from acetone.
'H NMR (free base) (250MHz. CDC13) δ (ppm): 8.64-8.55 (m, 3H), 8.35 (br s, IH), 8.05 (d, IH), 7.88 (d, IH), 7.83-7.78 (m, 2H), 7.43 (dd, IH), 738-730 (m. 2H), 7.28-7.12 (m. 4H), 6.79 (d, IH), 324 (br s, 4H). 2.64 (br s, 4H). 2.26 (s, 3H), 2.19 (s, 3H).
Example 28 N-[4-(4-Methylpiperazin-l-yi)quinolin-6-yl]-N'-[5-(pyrimidin-2-yl)naphth-l-yl]-urea
(E28)
The title compound was prepared from 5-(pyrimidin-2-yl)naphth-l-yl isocyanate (D34) and 6-amino-4-(4-methylpiperazin-l -yl)quinoline (D2) using a similar procedure to that described for Example 27. The free base was converted to monohydrochloride salt, as a yellow solid.
Η NMR (HCl salt) (250MHz. d6DMSO) δ (ppm): 153 (br. IH), 1 1.35 (br, IH), 1 1.05 (s, IH), 9.59 (s, IH). 8.78 (d, IH), 8.61 (s. IH), 8.47 (d, IH), 8.17 (dJH), 8.08 (d, IH), 7.98 (m, 3H), 7.68 (d, IH), 7.51-7.62 (m, 3H), 7.34 (d, IH), 4.23(br, 2H), 3.76 (br, 2H), 3.62 (br, 2H), 3.39 (obscured by water peak. 2H). 2.89 (s, 3H).
Example 29 N-[5-Bromonaphth-l-yl]-N'-[4-(piperazin-l-yl)quinolin-6-yl]-urea (E29)
N-[5-Bromonaphth-l-yl]-N'-[4-(4-tert-butoxycarbonylpiperazin-l-yl)quinolin-6-yl]-urea (D65, 200mg, 0.35mmol) in THF (30ml) was treated with cone. HCl (lml) and heated at reflux for 1.5 hours. A cream coloured precipitate was filtered off to give the hydrochloride salt of the title compound (27mg, 16%).
Η NMR (HCl salt) (250 MHz, d6DMSO) δ (ppm): 11.17 (s, IH), 9.80 (s, IH), 9.58 (br m, 2H), 8.75 (d, IH), 8.56 (m, 2H), 8.17 (m, 2H), 7,90-8.01 (m, 3H), 7.68 (t. IH), 7.52 (t, IH), 7.32 (d, IH), 3.92 (br m, 4H), 3.44 (br m, 4H, partially obscured). MH+ 476/478.
Example 30
2,3-Dihydro-8-(4-methyIpiperazin-l-yl)-l-[4-(pyridin-4-yl)naphth-l- ylaminocarbonyl]pyrroIo[2,3-g]quinoline (E30)
The title compound was prepared from 4-(pyridin-4-yl)-l-naphthylamine (D5) and 2,3- dihydro-8-(4-methylpiperazin-l-yl)pyrrolo[2,3-g]quinoline (D42) using a similar procedure to Example 1 as the hydrochloride salt, a yellow solid (67%).
Η NMR (HCl salt) (250 MHz, d6DMSO) δ (ppm): 1 1.74 (br s. IH), 9.41 (s, IH), 8.98 (d, 2H), 8.73 (d, IH), 8.41 (s, IH), 8.24 (d, IH), 8.13 (s, IH), 8.05 (d. 2H). 7.89 (d, IH), 7.60- 7.75 (m, 4H), 7.34 (d, IH), 4.55 (t, 2H), 4.10 (br d, 2H), 3.50-3.70 (m, 6H), 3.30 (m, 2H), 2.78 (d, 3H). MS: m/z = 515 (MH )
Example 31
2,3-Dihydro-8-(4-methylpiperazin-l-yl)-l-[5-(5-methyl-lJ,4-oxadiazol-3-yl)naphth-l- ylaminocarbonyl]pyrrolo[2,3-g]quinoline (E31) The title compound was prepared from 5-(5-methyl-1.2,4-oxadiazol-3-yl)-l-naphthylamine (D22) and 23-dihydro-8-(4-methylpiperazin-l -yi)pyrrolo[23-g]quinoline (D42) using a similar procedure to Example 1 as the hydrochloride salt, a yellow solid (83%). Η NMR (HCl salt) (250 MHz, d6DMSO) δ (ppm): 1 1.46 (br s, IH). 9.30 (s. IH). 8.71 (m. 2H). 8.39 (s, IH), 8.34 (d, IH), 8.21 (d, IH), 8.07 (s, IH), 7.64-7.77 (m, 3H), 7.30 (d. IH). 4.51 (t, 2H). 4.01 (br m, 2H), 3.58 (t, 2H), 320-3.40 (br m. 6H), 2.77(s, 3H). 2.76 (s. 3H). MS: m z = 520 (MH+)
Example 32
2,3-Dihydro-8-(4-methylpiperazin-l-yI)-l-[5-(pyrimidin-2-yloxy)naphth-l- ylaminocarbonyI]pyrrolo[2,3-g]quinoline (E32)
The title compound was prepared from 5-(pyrimidin-2-yloxy)-l-naphthylamine (D23) and 23-dihydro-8-(4-methylpiperazin-l-yl)pyrrolo[2,3-g]quinoline (D42) using a similar procedure to Example 1 as the hydrochloride salt, a yellow solid (47%). 'H NMR (HCl salt) (250 MHz, d6DMSO) δ (ppm): 11.59 (br s, IH), 9.27 (s, IH), 8.73 (d, IH), 8.65 (d, 2H), 8.40 (s, IH), 8.12 (s, IH), 8.01 (d, IH), 771 (m, IH), 7.51-7.63 (m, 3H), 7.42 (d, IH), 729-734 (m, 2H), 4.51 (t, 2H), 4.07 (br d, 2H), 3.51-3.68 (m, 6H), 3.31 (m, 2H), 2.78 (d, 3H). MS: m/z = 532 (MH+)
Example 33
9-(4-Methylpiperazin-l-yl)-l-[4-(pyridin-4-yI)naphth-l-ylaminocarbonyi]-l,2,3,4- tetrahydropyrido[2,3-g]quinoline (E33)
The title compound was prepared from 4-(pyridin-4-yl)-l-naphthylamine (D5) and 9-(4- methylpiperazin-l-yl)-l,2,3,4-tetrahydropyrido[2,3-g]quinoline (D52) using a similar procedure to Example 1 as the hydrochloride salt, an orange solid (59%). 'H NMR (HCl salt) (250 MHz, d6DMSO) δ (ppm): 1 1.57 (br s. IH), 9.50 (s, IH). 8.88 (d. 2H), 873 (d, IH), 836 (s, IH), 8.22 (d, IH), 7.98 (s, IH), 7.86 (m. 3H), 7.74 (d, IH), 7.57- 7.71 (m, 3H), 7.25 (d, IH), 4.18 (m, 2H), 4.09 (t, 2H), 320-3.80 (br m, 6H), 3.08 (t, 2H), 273 (s, 3H), 2.1 1 (m, 2H). MS: m z = 529 (MH+)
Example 34
9-(4-Methylpiperazin-l-yl)-l-[5-(pyrimidin-2-yloxy)naphth-l-ylaminocarbonyl]-l,2,3,4- tetrahydropyrido[2,3-glquinoline (E34) The title compound was prepared from 5-(pyrimidin-2-yloxy)-l-naphthyiamine (D23) and 9- (4-methylpiperazin-l -yl)-lJ3J-tetrahydropyrido[23-g]quinoline (D52) using a similar procedure to Example 1 as the hydrochloride salt, a yellow solid (64%). Η NMR (HCl salt) (250 MHz. d6DMSO) δ (ppm): 1 1.44 (br s. IH), 9.39 (s, IH), 8.73 (d. IH), 8.66 (d, 2H). 838 (s, IH). 8.00 (m, 2H), 7.49-7.69 (m. 4H), 7.41 (d. IH), 724-732 (m, 2H), 4.05-423 (m, 6H), 3.68 (t. 2H), 320-3.40 (m, 2H), 3.08 (t, 2H), 2.74 (d, 3H), 2.1 1 (t, 2H). MS: m/z = 546 (MH+)
Example 35
N-[8-Bromoquinolin-4-yl]-N'-[4-(4-methylpiperazin-l-yI)quinolin-6-yl]-urea (E35) The title compound was prepared from 8-bromoquinolin-4-yl isocyanate (D57) and 6-amino- 4-(4-methylpiperazin-l-yl)quinoline (D2) using a similar procedure to that described for Example 27 as a cream coloured solid (3%).
'H NMR (250MHz. CDC13) δ (ppm): 9.88 (br s, IH), 9.25 (br s, IH), 8.91 (d, IH), 8.65-8.61 (m, 2H), 8.47 (d, IH), 7.93 (d. IH), 7.80 (d, IH), 7.65 (d, IH), 7.01-6.95 (m, 2H), 6.85 (d. IH), 3.34 (br s. 4H), 2.70 (br s. 4H), 2.40 (s, 3H).
Example 36
N-[8-(2-Fluorophenyl)quinolin-4-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea
(E36)
The title compound was prepared from 8-(2-fluorophenyl)quinolin-4-yl isocyanate (D59) and
6-amino-4-(4-methylpiperazin- 1 -yl)quinoline (D2) using a similar procedure to Example 27 as a yellow solid (91%). This was converted to its hydrochloride salt as a yellow solid from acetone.
'H NMR (HCl salt) (250MHz, d^DMSO) δ (ppm): 12.19 (s, IH). 1 172 (br s, IH), 1 1.32 (br s, IH), 9.29 (d, IH). 8.87-874 (m. 3H), 8.59 (s, IH), 8.23 (d. IH), 8.06-7.92 (m, 3H), 7.67-
7.56 (m, 2H), 7.48-739 (m, 3H), 4.33 (br d, 2H), 3.88 (br t. 2H), 3.55 (br. 4H), 2.91 (s, 3H).
Example 37
N-[8-(2-Methoxypheny_)quinoIin-4-yI]-N'-[4-(4-methylpiperazin-l-yl)quinoIin-6-yl]- urea (E37)
The title compound was prepared from 8-(2-methoxyphenyl)quinolin-4-yl isocyanate (D61 ) and 6-amino-4-(4-methylpiperazin-l-yl)quinoline (D2) using a similar procedure to Example
27 as a yellow solid (8%). Η NMR (250MHZ. CDC13) δ (ppm): 9.67 (br s, IH), 8.85-875 (m, 2H). 8.66 (d. IH), 8.59 (d. I H), 8.39 (d. IH), 7.85 (d. IH), 7.55-7.51 (m, 2H), 7.24-7.04 (m. 4H). 6.87-679 (m, 3H), 3.43 (s. 3H), 332 (br s. 4H). 2.70 (br s. 4H). 2.38 (s, 3H).
Examples 38 - 56
The following compounds were prepared by a similar procedure to that described for Example 27 using the appropriate isocyanate together with 6-amino-4-(4-methylpiperazin-l- yl)quinoline (D2)
Figure imgf000046_0001
Figure imgf000047_0001
Examples 57 - 68
The following compounds were prepared from the appropriate carboxylic acid and 6-amino- 4-(4-methylpiperazin-l-yl)quinoline (D2) using l-(3-dimethylaminopropyl)-3- ethylcarbodiimide as coupling reagent.
Figure imgf000047_0002
Figure imgf000048_0001
Example 67
N-[4-(4-MethyIpiperazin-l-yl)quinolin-6-yl]-N'-(5,6,7,8-tetrahydro-5-oxo-2- naphthalenylj-urea (E67)
The title compound was prepared from 6-amino-3,4-dihydro-l(2H)-naphthalenone and 6- amino-4-(4-methylpiperazin-l-yl)quinoline (D2) using a similar procedure to Example 1 as a yellow foam (47%).
Η NMR (250 MHz, CDC13) δ (ppm): 9.2 (s, IH), 8.95 (s, IH), 8.6 (d, IH), 8.5 (s, IH), 7.9 (d, IH), 7.8 (d, IH), 7.6 (s, IH), 7.2 (d, IH), 7.05 (d, IH), 6.8 (d, IH), 3.25 (br s, 4H), 2.85 (m, 2H), 2.6 (m, 6H), 2.3 (s, 3H), 2.05 (m, 2H).
Example 68 N-{4-(4-Methylpiperazin-l-yl)quinoIin-6-yl]-N'-[5-oxoindan-2-yl]-urea (E68)
The title compound was prepared from 5-amino-l-indanone and 6-amino-4-(4- methylpiperazin-l-yl)quinoline (D2) using a similar procedure to Example 1 as a yellow foam (20%).
'H NMR (250 MHz, CDC13) δ (ppm): 8.8 (br s, 2H), 8.65 (d, IH), 8.45 (d, IH), 7.95 (s, IH), 7.85 (d, IH), 7.6 (d, IH), 7.25 (dd, IH), 7.05 (d, IH), 6.85 (d, IH), 3.3 (br s, 4H), 3.1 (m, 2H), 2.7 (m, 6H), 2.4 (s, 3H).
Example 69
2,3-Dihydro-8-(4-methylpiperazin-l-yl)-l-[(5,6,7,8-tetrahydro-5-oxo-2- naphthalenyl)aminocarbonyl]pyrrolo[2,3-g]quinoline (E69)
The title compound was prepared from 6-amino-3.4-dihydro-l(2H)-naphthalenone and 2.3- dihydro-8-(4-methylpiperazin- l-yl)pyrrolo[2,3-g]quinoline (D42) using a similar procedure to Example 1 as the hydrochloride salt, a yellow solid (55%). 'H NMR (HCl salt) (250 MHz. d6DMSO) δ (ppm): 1 1.74 (br s, IH), 9.29 (s. IH), 8.73 (d, IH), 8.42 (s, IH). 8.07 (s, IH). 7.85 (d, IH), 7.66 (m, 2H), 736 (d, IH), 4.39 (t, 2H). 4.16 (t, 2H), 3.79 (t. 2H). 325-3.62 (m. 6H). 2.93 (t. 2H), 2.88 (d, 3H). 2.57 (t, 2H). 2.04 (m, 2H). MH+ 456.
Example 70
9-(4-Methylpiperazin-l-yl)-l-[(5-oxo-5,6,7,8-tetrahydronaphth-6-yl)aminocarbonyI]- l,2,3,4-tetrahydropyrido[2,3-g]quinoline (E70)
The title compound was prepared from 6-amino-3,4-dihydro-l(2H)-naphthalenone and 9-(4- methylpiperazin- l-yl)-lJ,3,4-tetrahydropyrido[2,3-g]quinoline (D52) using a similar procedure to Example 1 as the hydrochloride salt, a dark yellow solid (71%). Η NMR (HCl salt) (250 MHz, d6DMSO) δ (ppm): 11.59 (br s, IH), 9.69 (s, IH), 8.75 (d, IH), 8.13 (s, IH), 8.00 (s, IH), 7.83 (d, IH), 7.52 (m, 2H), 7.27 (d. IH), 4.13-4.18 (m, 2H), 3,87 (t, 2H), 3.64 (br m, 2H), 3.27 (m, 4H), 3.01 (t, 2H), 2.91 (t, 2H), 2.71 (s, 3H), 2.56 (t, 2H), 2.01 (m, 4H). MH+ 470.
Pharmacological Data
The affinities of the compounds of this invention were determined by methods described above.
5-HTJ A> 5-HTJ B and 5-HTJ D Receptor Binding
Examples 1-5, 7, 9, 10, 13, 14, 18-21, 25-27, 30, 35-37, 39. 40, 44, 46, 58, 60 and 66-68 had pKi values > 8.5 at 5-HTj A> 5-HTJ B and 5-HTJ Q receptors

Claims

1. A compound of formula (I) or a salt thereof:
Figure imgf000050_0001
(I) in which Ra is selected from a group of formula (i), (ii) or (iii);
Group of formula (i)
Figure imgf000050_0002
in which pi is phenyl, bicyclic aryl, a 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;
R1 is hydrogen, halogen, Ci.galkyl, C3_6cycloalkyl, C^galkoxy, hydroxy, hydroxyCi. galkyl, hydroxyC \ .galkoxy, C╬╣_6alkoxyC╬╝6alkoxy, C^alkanoyl, nitro, trifluoromethyl, cyano, SR9, SOR9, SO R9, SO2NR10RH, CO2Rl┬░, CONRIORH,
CONR10(CH2)cCO2Rπ, (CH2)cNR10R l, (CH2)CCONR10RU, (CH2)CNR1°CORU,
(CH2)cCO2C1.6alkyl,CO2(CH2)cORl0,NRl┬░R1l,NRlOCO2Rll,NRlOCONRl╬╕Rll,
CR10=NOR11, CNR1┬░=N0R11, where R9, R10 and Rl 1 are independently hydrogen or
C╬╣_6alkyl and c is 1 to 4; a is 0, 1 or 2; and
R2 is halogen, Cj.galkyl, C3_6cycloalkyl, C3_6cycloalkenyl. Ci.^alkoxy, C╬╣_6alkanoyl. aryl, acyloxy, hydroxy, nitro. trifluoromethyl, cyano, CO2R10, CONR1┬░R11, NR1┬░R11 where R^ and Rl are as defined above;
Group of formula (ii)
Figure imgf000051_0001
wherein P^ and P^ are independently phenyl, bicyclic aryl, a 5- to 7- membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;
A is a bond or oxygen, S(O)m where m is 0 to 2, carbonyl. CH2 or NR^ where R^ is hydrogen or C ^.galkyl;
Rl is as defined above for formula (i) or is a 5 to 7-membered heterocyclic ring, containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur, optionally substituted by C \ . galkyl, halogen or C i-^alkanoyl; a and b are independently 0, 1 or 2; and
R2 and R are independently halogen. C^alkyl, C3_6cycloalkyl, C3_6cycloalkenyl, C\_ galkoxy, C ^galkanoyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano. CO RlO,
CONRI ORI 1 , NR ORI 1 where Rl┬░ and Rl 1 are as defined above;
Group of formula (iii)
(R2)a
0 = C E
(iii) in which the ring E is a 5, 6 or 7 -membered carbocyclic ring optionally substituted by one or more Ci .^alkyl groups, fused at the 2,3- or 3,4-positions of the adjacent phenyl ring, the ring E being optionally fused to a further phenyl ring optionally substituted by one or more substituents independently selected from C ^alkyl and halo; a is 0, 1 or 2; and
R- is halogen. C j ^alkyl, C3.gcycloalkyl, C3_6cycloalkenyl, C ^alkoxy. C ^alkanoyl, aryl, acyloxy, hydroxy, nitro. trifluoromethyl, cyano, CO2Rl┬░, CONR1┬░R1 1 , NR1┬░R11 where RlO and Rl 1 are as defined above;
L is a group of formula
- Y-C(=O)-DG - or -C(=O)-DG- or -DG-C(=O)- in which Y is - NH -, NR^ where R^ is C^alkyl, or Y is - CH2 - or - O -;
D is nitrogen, carbon or a CH group, G is hydrogen or C \ .^alkyl providing that D is nitrogen or a CH group, or G together with Rbl forms a group W where W is (CRl6Rl )t where t is
2. 3 or 4 and R' 6 and Rl ? are independently hydrogen or C j .(-.alkyl or W is (CR16R1 )U-J where u is 0, 1, 2 or 3 and J is oxygen, sulphur, CRl6=CR1 7, CR16=N, =CR160, =CRl6S or =CR1 "-NRI ' provided that u is not 0 when J is oxygen or sulphur;
X is nitrogen or carbon;
R┬░l , R┬░2 and R J are independently hydrogen, halogen, hydroxy. C^galkyl,
C2_6alkenyl, C3_6cycloalkyl, trifluoromethyl, C i.galkoxy or aryl, or Rbl together with G forms a group W as defined above;
Rc is hydrogen or C [.galkyl; and is a single bond when X is nitrogen or a single or double bond when X is carbon.
2. A compound according to claim 1 in which P 1 is a phenyl, naphthyl or a quinoline group.
3. A compound according to claim 1 or 2 in which Rl is halogen or a Cj.galkyl.
4. A compound according to any ofthe preceding claims in which the group L is a group of formula:-
-Y-C(=O)-(DG)- in which Y, D and G are as defined in formula (I).
5. A compound according to any ofthe preceding claims in which Y is -NH-.
6. A compound according to any ofthe preceding claims in which D is nitrogen and G is hydrogen.
7. A compound according to any of the preceding claims in which Rbl, R┬░2 and Rb-> are independently hydrogen, halogen or Cj-^alkoxy.
8. A compound according to any of the preceding claims in which X is nitrogen.
9. A compound according to claim 1 which is: N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[4-(4-methylpiper^in-l-yl)quinolin-6-yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[4-(pyridin-4-yl)naphth-l -yl]-urea,
N-[4-(4-Methylpiperazin- 1 -y l)quinolin-6-yl]-N'-[5-(pyridin-4-y l)naphth- 1 -y l]-urea
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[quinolin-6-yl]-urea,
4-Bromo-N-[4-(4-methylpiperazin- 1 -yl)quinolin-6-yl]naphth- 1 -ylacetamide,
5-Bromo-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]naphth-l -ylacetamide.
N-[4-(4-Methylpiperazin- 1 -yl)quinolin-6-y l]-4-(pyridin-4-yl)naphth- 1 -ylacetamide,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-5-(pyridin-4-yl)naphth-l -ylacetamide,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[4-(pyridin-4-yl)-3-trifluoromethylphenyl]- urea.
N-[3-Cyano-4-(pyridin-4-yl)phenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[quinolin-5-yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[quinolin-8-yl]-urea.
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[quinolin-3-yl]-urea,
2,3-Dichloro-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]phenylacetamide,
5-(4-Acetylphenyl)-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]naphth-l -ylacetamide,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[quinolin-4-yl]-urea,
N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[4-(l-methylpiperidin-4-yl)quinolin-6-yl]-urea,
N-[3-Methyl-4-(6-methylpyridin-2-yl)phenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]- urea,
N-[4-(2,6-Dimethylpyridin-4-yl)-3-methylphenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6- yl]-urea,
N-[5-Cyanonaphth-l-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[5-(5-Methyl-l,2,4-oxadiazol-3-yl)naphth-l-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6- yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[5-(pyrimidin-2-yloxy)naphth-l-yl]-urea,
N-[5-Acetylnaphth- 1 -yl]-N'-[4-(4-methylpiperazin- 1 -yl)quinolin-6-y l]-urea,
N-[5-Bromonaphth-l-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[5-(6-Methy lpyridin-2-yl)naphth- 1 -yl]-N'-[4-(4-methylpiperazin- 1 -yl)quinolin-6-yl]-urea,
N-[5-(2-Methylpyridin-5-yl)naphth- 1 -yl]-N'-[4-(4-methylpiperazin- 1 -y l)quinolin-6-yl]-urea,
N-[5-(2-Methylpyridin-3-yl)naphth-l-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[5-(pyrimidin-2-yl)naphth-l-yl]-urea,
N-[5-Bromonaphth- 1 -yl]-N'-[4-(piperazin- 1 -yl)quinolin-6-yl]-urea.
2.3-Dihydro-8-(4-methylpiperazin- 1 -yl)- 1 -[4-(pyridin-4-yl)naphth- 1 - ylaminocarbonyl]pytτolo[2,3-g]quinoline, 2,3-Dihydro-8-(4-methylpiperazin-l-yl)-l-[5-(5-methyl-12J-oxadiazol-3-yl)naphth-l- ylaminocarbonyl]pyrrolo[2,3-g]quinoline,
2,3-Dihydro-8-(4-methylpiperazin- 1 -yl)- 1 -[5-(pyrimidin-2-y loxy )naphth- 1 - ylaminocarbonyl]pyrrolo[23-g]quinoline,
9-(4-Methylpiperazin- 1 -yl)- 1 -[4-(pyridin-4-yl)naphth- 1 -ylaminocarbonyl]- 12,3,4- tetrahydropyrido[23-g]quinoline,
9-(4-Methylpiperazin- 1 -yl)- 1 -[5-(pyrimidin-2-yloxy)naphth- 1 -ylaminocarbonyl]- 1 ,2,3,4- tetrahydropyrido[23-g]quinoline.
N-[8-Bromoquinolin-4-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[8-(2-FluorophenyI)quinolin-4-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea.
N-[8-(2-Methoxyphenyl)quinolin-4-yl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[2-Biphenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[2,
3-Dichlorophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N'-[4-Biphenyl]-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea.
N-[3,
4-Dichlorophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[4-Chlorophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[3-Cyanophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[4-phenoxyphenyl]-urea,
N-[4-Bromophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[4-Acetylphenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[2-Bromophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[3,
5-Bis(trifluoromethyl)phenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[3-Acetylphenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[2,6-Difluorophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[3-Bromophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[naphth-l-yl]-urea,
N-[2,6-Dichlorophenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yI]-urea,
N-[4-Chloro-2-methylphenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea,
N-[4-Bromo-3-methylphenyl]-N'-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]-urea.
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-2-nitrophenylacetamide,
4-Bromo-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]phenylacetamide,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-4-biphenylacetamide.
3,4-Dichloro-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]benzamide,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]naphth-2-ylacetamide.
4-Dimethylamino-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]phenylacetamide. 3,4-Difluoro-N-[4-(4-methylpiperazin-l-yl)quinolin-6-yl]phenylacetamide.
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-3-phenoxyphenyIacetamide.
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]naphth-l-ylcarboxamide,
N-[4-(4-Methylpiperazin- 1 -y l)quinolin-6-yl]-4-phenoxybenzamide,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl]- urea,
N-[4-(4-Methylpiperazin-l-yl)quinolin-6-yl]-N'-[5-oxoindan-2-yl]-urea,
2,3-Dihydro-8-(4-methylpiperazin-l-yl)-l -[(5,
6,
7,
8-tetrahydro-5-oxo-2- naphthalenyl)aminocarbonyi]pyrrolo[2,3-g]quinoline,
9-(4-Methylpiperazin- 1 -yl)- 1 -[(5-oxo-5,6,7,8-tetrahydronaphth-6-yl)aminocarbonyl]- 1 ,2,3,4- tetrahydropyrido[2,3-g]quinoline or pharmaceutically acceptable salts thereof.
10. A process for the preparation of a compound of formula (I) which comprises:
(a) where L is -C(=O)-DG - or -DG-(C=O)-, coupling a compound of formula (II):
R -Ll (II) with a compound of formula (III):
Figure imgf000055_0001
in which Ra, R l , Rb2^ ╬▓b3, RC and x are as defined in formula (I) and Li and \A contain the appropriate functional groups which are capable of reacting together to form the L moiety; or
(b) where L is - Y -C(=O)-DG in which D is nitrogen and Y is NH, coupling a compound of formula (IV):
Ra -NC(=O) (IN) in which Ra is as defined in formula (I) or a protected derivative thereof, with a compound of formula (V):
GNH
,b3
N
RD
R ,b"2
(V) in which Rbl, Rb2^ RM^ RC Q and X .are as defined in formula (I), or a protected derivative thereof; or
(c) where L is - Y -C(=O)-DG - in which D is nitrogen and Y is NH or NR^, reacting a compound of formula (VI):
R -NH or R -NR$H (VI) in which Ra and R^ are as defined in formula (I) with a compound of formula (V) together with an appropriate urea forming agent; or
(d) where L is - Y -C(=O)-DG - in which D is nitrogen and Y is CH2 or O. reacting a compound of formula (VII):
Ra _╬│_ (co) - L3 (VII) in which Ra is as defined in formula (I), and L3 is an appropriate leaving group, with a compound of formula (V); or
(e) where L is - Y -C(=O)-DG - in which D is CH and Y is NH, reacting a compound of formula (VI):
Ra -NH2 (VI) in which Ra is as defined in formula (I) with a compound of formula (VIII): Rc
O X
L3 DG- ,b3 b1
R b2
R
(VIII) in which G, X, Rbl, Rb2; Rbj 3^ RC are as defined in formula (I) and lA is an appropriate leaving atom; and optionally thereafter:
ΓÇó removing any protecting groups,
ΓÇó converting a compound of formula (I) into another compound of formula (I),
ΓÇó forming a pharmaceutically acceptable salt.
11. A compound according to any of claims 1 to 9 for use in therapy.
12 A compound according to any of claims 1 to 9 for use in the treatment of depression.
13. A pharmaceutical composition which comprises a compound according to any of claims 1 to 9 and a pharmaceutically acceptable carrier.
PCT/EP1998/007804 1997-12-12 1998-12-02 Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists WO1999031086A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP98965729A EP1047691A1 (en) 1997-12-12 1998-12-02 Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
CA002313125A CA2313125A1 (en) 1997-12-12 1998-12-02 Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
JP2000539010A JP2002508366A (en) 1997-12-12 1998-12-02 Quinoline piperazine and quinoline piperidine derivatives, methods for their preparation, and their use as complex 5-HT1A, 5-HT1B and 5-HT1D receptor antagonists

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9726364.4A GB9726364D0 (en) 1997-12-12 1997-12-12 Novel Compounds
GB9726364.4 1997-12-12
GBGB9726905.4A GB9726905D0 (en) 1997-12-19 1997-12-19 Novel compounds
GB9726905.4 1997-12-19
GB9800317.1 1998-01-07
GBGB9800317.1A GB9800317D0 (en) 1998-01-07 1998-01-07 Novel compounds

Publications (1)

Publication Number Publication Date
WO1999031086A1 true WO1999031086A1 (en) 1999-06-24

Family

ID=27269131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/007804 WO1999031086A1 (en) 1997-12-12 1998-12-02 Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists

Country Status (4)

Country Link
EP (1) EP1047691A1 (en)
JP (1) JP2002508366A (en)
CA (1) CA2313125A1 (en)
WO (1) WO1999031086A1 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035919A2 (en) * 1998-12-17 2000-06-22 Smithkline Beecham Plc Quinoline derivatives
WO2001007411A1 (en) * 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
JP2001106673A (en) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd Biarylurea derivative
WO2001032626A1 (en) * 1999-11-05 2001-05-10 Smithkline Beecham P.L.C. Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity
WO2001032659A1 (en) * 1999-11-05 2001-05-10 Smithkline Beecham P.L.C. Isoquinoline and quinazoline derivatives for the treatment of cns disorders
WO2001042213A1 (en) * 1999-12-07 2001-06-14 Theravance, Inc. Urea compounds having muscarinic receptor antagonist activity
WO2003015769A1 (en) * 2001-08-17 2003-02-27 Aventis Pharma Deutschland Gmbh Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
WO2005014552A1 (en) * 2003-07-18 2005-02-17 Glaxo Group Limited Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
US6858621B2 (en) 2002-04-26 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
US7141671B2 (en) 2003-02-14 2006-11-28 Theravance, Inc. Biphenyl derivatives
US7220856B2 (en) 2002-06-27 2007-05-22 Schering Aktiengesellschaft Substituted quinoline CCR5 receptor antagonists
US7238709B2 (en) 1999-12-07 2007-07-03 Theravance, Inc. Therapeutic carbamates
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7576215B2 (en) 2003-12-12 2009-08-18 Wyeth Quinolines and pharmaceutical compositions thereof
US7645778B2 (en) 2005-01-19 2010-01-12 Bristol-Myers Squibb Company Heteroaryl compounds as P2Y1 receptor inhibitors
US7700620B2 (en) 2005-06-27 2010-04-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7728008B2 (en) 2005-06-27 2010-06-01 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7816382B2 (en) 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US7960551B2 (en) 2006-02-10 2011-06-14 Glaxo Group Limited Compound
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
WO2014025833A2 (en) * 2012-08-07 2014-02-13 University Of Washington Through Its Center For Commercialization Fluorescent dyes and related methods
US10752640B2 (en) 2014-08-01 2020-08-25 Nuevolution A/S Compounds active towards bromodomains
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032967A1 (en) * 1994-05-28 1995-12-07 Smithkline Beecham Plc Amide derivatives having 5ht1d-antagonist activity
WO1997007120A1 (en) * 1995-08-11 1997-02-27 Smithkline Beecham Plc Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht1d receptor antagonists
WO1999007700A1 (en) * 1997-08-09 1999-02-18 Smithkline Beecham Plc Bicyclic compounds as ligands for 5-ht1 receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032967A1 (en) * 1994-05-28 1995-12-07 Smithkline Beecham Plc Amide derivatives having 5ht1d-antagonist activity
WO1997007120A1 (en) * 1995-08-11 1997-02-27 Smithkline Beecham Plc Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht1d receptor antagonists
WO1999007700A1 (en) * 1997-08-09 1999-02-18 Smithkline Beecham Plc Bicyclic compounds as ligands for 5-ht1 receptors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PAUWELS P.J. & PALMIER C.: "Functional effects of the 5-HT1D receptor antagonist GR 127,935 at human 5-HT1D.alpha., 5-HT1D.beta., 5-HT1A and opossum 5-HT1B receptors", EUROPEAN JOURNAL OF PHARMACOLOGY. MOLECULAR PHARMACOLOGY SECTION, vol. 290, no. 2, 1995, pages 95 - 103, XP000612639 *
SCHOEFFTER P. & HOYER D.: "Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: Do discriminatory 5-HT1B receptor ligands exist?", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 339, no. 6, 1 June 1989 (1989-06-01), pages 675 - 683, XP000576360 *
STARKEY S.J. & SKINGLE M.: "5-HT1D as well as 5-HT1A autoreceptors modulate 5-HT release in the guinea-pig dorsal Raphé nucleus", NEUROPHARMACOLOGY, vol. 33, no. 3/4, 1994, pages 393 - 402, XP000654898 *

Cited By (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035919A3 (en) * 1998-12-17 2000-10-26 Smithkline Beecham Plc Quinoline derivatives
WO2000035919A2 (en) * 1998-12-17 2000-06-22 Smithkline Beecham Plc Quinoline derivatives
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
US7456203B2 (en) 1999-02-16 2008-11-25 Theravance, Inc. Muscarinic receptor antagonists
WO2001007411A1 (en) * 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
JP2001106673A (en) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd Biarylurea derivative
EP1557168A3 (en) * 1999-07-26 2007-05-23 Banyu Pharmaceutical Co., Ltd. Biarylurea Derivatives
US7354946B2 (en) 1999-07-26 2008-04-08 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
US6958333B1 (en) 1999-07-26 2005-10-25 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
WO2001032659A1 (en) * 1999-11-05 2001-05-10 Smithkline Beecham P.L.C. Isoquinoline and quinazoline derivatives for the treatment of cns disorders
JP2003513075A (en) * 1999-11-05 2003-04-08 スミスクライン ビーチャム パブリック リミテッド カンパニー Isoquinoline and quinazoline derivatives having complex 5HT1A, 5HT1B and 5HT1D receptor activity
WO2001032626A1 (en) * 1999-11-05 2001-05-10 Smithkline Beecham P.L.C. Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity
US6635764B2 (en) 1999-12-07 2003-10-21 Theravance, Inc. Therapeutic ureas
AU782232B2 (en) * 1999-12-07 2005-07-14 Theravance Biopharma R&D Ip, Llc Urea compounds having muscarinic receptor antagonist activity
WO2001042213A1 (en) * 1999-12-07 2001-06-14 Theravance, Inc. Urea compounds having muscarinic receptor antagonist activity
US7238709B2 (en) 1999-12-07 2007-07-03 Theravance, Inc. Therapeutic carbamates
WO2003015769A1 (en) * 2001-08-17 2003-02-27 Aventis Pharma Deutschland Gmbh Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
US6858621B2 (en) 2002-04-26 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
US7220856B2 (en) 2002-06-27 2007-05-22 Schering Aktiengesellschaft Substituted quinoline CCR5 receptor antagonists
US7521561B2 (en) 2003-02-14 2009-04-21 Theravance, Inc. Biphenyl derivatives
US7514558B2 (en) 2003-02-14 2009-04-07 Theravance, Inc. Biphenyl derivatives
US8969571B2 (en) 2003-02-14 2015-03-03 Theravance Respiratory Company, Llc Biphenyl derivatives
US7345175B2 (en) 2003-02-14 2008-03-18 Theravance, Inc. Biphenyl derivatives
US8618131B2 (en) 2003-02-14 2013-12-31 Theravance, Inc. Biphenyl derivatives
US8242135B2 (en) 2003-02-14 2012-08-14 Theravance, Inc. Biphenyl derivatives
US7355046B2 (en) 2003-02-14 2008-04-08 Theravance, Inc. Biphenyl derivatives
US7141671B2 (en) 2003-02-14 2006-11-28 Theravance, Inc. Biphenyl derivatives
US7879879B2 (en) 2003-02-14 2011-02-01 Theravance, Inc. Biphenyl derivatives
US7524959B2 (en) 2003-02-14 2009-04-28 Theravance, Inc. Biphenyl derivatives
US7732600B2 (en) 2003-07-18 2010-06-08 Glaxo Group Limited Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
EP1876174A1 (en) * 2003-07-18 2008-01-09 Glaxo Group Limited Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
CN100441571C (en) * 2003-07-18 2008-12-10 葛兰素集团有限公司 Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
JP2006528146A (en) * 2003-07-18 2006-12-14 グラクソ　グループ　リミテッド Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
US7459456B2 (en) 2003-07-18 2008-12-02 Glaxo Group Limited Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
US7592346B2 (en) 2003-07-18 2009-09-22 Glaxo Group Limited Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
US7279481B2 (en) 2003-07-18 2007-10-09 Glaxo Group Limited Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
EP2145622A1 (en) * 2003-07-18 2010-01-20 Glaxo Group Limited Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
WO2005014552A1 (en) * 2003-07-18 2005-02-17 Glaxo Group Limited Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US8247564B2 (en) 2003-11-21 2012-08-21 Theravance, Inc. Compounds having BETA2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7838535B2 (en) 2003-11-21 2010-11-23 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7842704B2 (en) 2003-11-21 2010-11-30 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7576215B2 (en) 2003-12-12 2009-08-18 Wyeth Quinolines and pharmaceutical compositions thereof
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7645778B2 (en) 2005-01-19 2010-01-12 Bristol-Myers Squibb Company Heteroaryl compounds as P2Y1 receptor inhibitors
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US7700620B2 (en) 2005-06-27 2010-04-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7816382B2 (en) 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
US8329718B2 (en) 2005-06-27 2012-12-11 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7728008B2 (en) 2005-06-27 2010-06-01 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7960551B2 (en) 2006-02-10 2011-06-14 Glaxo Group Limited Compound
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2014025833A2 (en) * 2012-08-07 2014-02-13 University Of Washington Through Its Center For Commercialization Fluorescent dyes and related methods
WO2014025833A3 (en) * 2012-08-07 2014-06-26 University Of Washington Through Its Center For Commercialization Fluorescent dyes and related methods
US9410947B2 (en) 2012-08-07 2016-08-09 University Of Washington Through Its Center For Commercialization Fluorescent dyes and related methods
US9702870B2 (en) 2012-08-07 2017-07-11 University Of Washington Through Its Center For Commercialization Fluorescent dyes and related methods
US10752640B2 (en) 2014-08-01 2020-08-25 Nuevolution A/S Compounds active towards bromodomains
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Also Published As

Publication number Publication date
CA2313125A1 (en) 1999-06-24
EP1047691A1 (en) 2000-11-02
JP2002508366A (en) 2002-03-19

Similar Documents

Publication Publication Date Title
EP1047691A1 (en) Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
US10494371B2 (en) Bromodomain inhibitors
JP6918088B2 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazine as a modulator of GPR139
AU765020B2 (en) Piperazine derivatives as 5-HT1B antagonists
JP2007008816A (en) New isoquinoline derivative
CA2500083A1 (en) Tetrahydroquinoline derivatives as crth2 antagonists
JP2008507534A (en) Furanopyridine derivatives and methods of use
TW201035055A (en) Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
WO1998047868A1 (en) Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
TW200843777A (en) Inhibitors of the hedgehog pathway
NO313293B1 (en) Substituted pyrido or pyrimido-containing 6,6- or 6,7-bicyclic derivatives, their use and pharmaceutical composition
CA2355234A1 (en) Quinoline derivatives
JP2002534508A (en) Phenylphenanthridine having PED-IV inhibitory action
US20100240648A1 (en) Hexahydro-pyrrolo-isoquinoline compounds
US20090012056A1 (en) Quinoline Compounds Capable of Binding the Cb2 and/or the 5-Ht6 Receptor
EP1003738B1 (en) Bicyclic compounds as ligands for 5-ht1 receptors
WO2013013614A1 (en) 4-(3-heteroarylarylamino)quinazoline and 1-(3-heteroarylarylamino)isoquinoline as hedgehog pathway inhibitor and use thereof
JP2006517976A (en) New compounds
US5472966A (en) Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
US4035368A (en) Substituted 3-(1H-tetrazol-5-yl)-quinoline compounds
US6031097A (en) 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
JP2004529124A (en) Piperazine derivatives as 5-HT1B ligands and uses thereof
WO1999029666A1 (en) Arylpiperazine and arylpiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
JP2001512491A (en) 1- (isoquinolin-1-yl) -4- (1-phenylmethyl) piperazine; a dopamine receptor subtype-specific ligand
US5972945A (en) 2-aminoalkylaminoquinolines; dopamine receptor subtype specific ligands

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998965729

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2313125

Country of ref document: CA

Ref country code: CA

Ref document number: 2313125

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09555999

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998965729

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998965729

Country of ref document: EP